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Abstract
The Gram negative bacillus Mannheimia haemolytica is a natural inhabitant of the 
upper respiratory tract in ruminants and the most common secondary agent of the 
bovine respiratory disease complex. It is known to produce the extracellular 
neuraminidase NanH, which has a yet unknown biological role but is suspected to 
be important for bacterial adhesion to host cells, colonisation, capsule synthesis 
and biofilm formation. The structure of NanH is not known therefore, the functional 
domains of NanH, the tertiary structure and the residues involved in catalysis were 
predicted by sequence homology to the coordinates of other neuraminidases 
solved by crystallography. The catalytic domain was delimited from residues 23 to 
435 and purified. The predicted catalytic residues were substituted in the 
recombinant NanH for confirmation of their role in hydrolysis of sialic acid. The 
function of the additional domains is unknown but analysis of NanH sequence and 
other associated genes found in the chromosome of M. haemolytica, suggest the 
presence of an autotransporter domain. The role of NanH in colonisation and 
infection is not known however, molecular characterisation is presented in this 
work. These data provide the basic knowledge required for future studies on using 
Nanh as a therapeutic and prophylactic target.
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1 Introduction
1.1 Bovine respiratory disease
Pneumonia in ruminants has always represented one of farmers’ major concerns 
due to the high economic losses caused by  surges in calf mortality  figures and 
decreased growth rates. The incidence of the disease has been reported to be as 
high as 64% in beef cattle in The United States (Schneider et al., 2009), causing a 
decrease of nearly 6% in the average daily growth (Wittum et al., 1996).
In addition to the losses caused by a decrease in the general quality  of the meat 
and the yield obtained after slaughter, treatment and prevention have been 
reported to represent 7% of total production costs in the bovine industry (Snowder 
et al., 2007). A different study in the USA estimated annual losses for beef cattle 
producers of $500 million (Miles, 2009).
The bovine respiratory  disease (BRD) is caused by the interaction of three 
components: adverse environmental factors that provide a suitable environment 
for respiratory disease, a primary agent which is usually  a respiratory viral 
pathogen and a secondary agent which are bacteria from the family 
Pasteurellaceae that naturally  inhabit the upper respiratory tract but reach the 
lower respiratory  tract as opportunistic pathogens (Aitken, 2007, Maxie and Jubb, 
2007, Panciera and Confer, 2010). Bovines are not exclusively affected by BRD, it 
is a problem that extends to all ruminants such as ovines, caprines and small 
camelids either domestic or wild.
BRD is also known as shipping fever due to the occurrence of pneumonia after 
transportation even though shipping is just one of the possible external factors that 
can cause the disease. Some authors also refer to BRD as ovine or bovine 
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pasteurellosis because the secondary agents are the responsible for causing the 
pneumonic lesions (Saadati et al., 1997, Aitken, 2007). 
1.1.1 Aetiology
As previously mentioned, BRD is a complex formed by environmental factors, 
primary agents and secondary agents (Figure 1). The environmental factors 
represent external disturbances that create stressful conditions for the animals and 
affect the respiratory  tract directly or indirectly. High variations in temperature and 
humidity  in a short time can greatly disturb the respiratory  tract. Therefore the 
region and the season of the year can have a big influence if the animals have 
inadequate housing. Other stressful situations are related to inadequate 
husbandry and farming practices such as a reduced food and water intake, high 
population density and poor hygienic conditions. However, some routine veterinary 
procedures such as transportation and weaning can predispose to BRD. Calves 
who fail to receive colostrum in the first 12 hours after birth, are at high risk of 
developing BRD (Edwards, 2010, Hodgson et al., 2012) .
The most common primary agents are bovine herpes virus-1 (BHV-1) (Yates et al., 
1983), bovine parainfluenza virus-3 (BPI-3) (Jericho et al., 1982), bovine 
respiratory  syncytial virus (BRSV) (Trigo et al., 1984, Sharma and Woldehiwet, 
1990), bovine viral diarrhoea virus (BVDV) (Fulton et al., 2000) and Mycoplasma 
sp. (Dassanayake et al., 2010, Besser et al., 2014). Even though primary agents 
can cause respiratory  disease in ruminants on their own, most of them only cause 
death when they  are associated with a secondary bacterial infection hence, their 
importance relies more on the various mechanisms they use to facilitate infection 
of bacterial opportunists (Panciera and Confer, 2010). For instance, infection with 
BHV-1 can increase bacterial colonisation by lysis of respiratory epithelial cells 
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during multiplication therefore, debilitating the host tissue. BRSV is known to 
multiply  in ciliated respiratory cells and type II pneumocytes which can decrease 
bacterial clearance (Valarcher and Taylor, 2007, Sacco et al., 2014). The immune 
response is also known to be affected by BHV-1 by induction of apoptosis of CD4+ 
T cells, peripheral blood mononuclear cells (PBMC), polymorphonuclear 
neutrophils (PMN) and inhibition of CD8+ T cell activation (Jones and Chowdhury, 
2007, Muylkens et al., 2007).
Mannheimia haemolytica, previously known as Pasteurella haemolytica, is the 
main secondary agent responsible for causing pneumonia in ruminants (Aitken, 
2007, Zecchinon et al., 2005). The former species Pasteurella haemolytica was 
divided into two biotypes depending on the biochemical property to either ferment 
arabinose or trehalose as biotype A and T respectively. They were subsequently 
classified in thirteen A serotypes (A1, A2, A5, A6, A7, A8, A9, A12, A13, A14, A16 
and A17) and four T serotypes (T3, T4, T10 and T15) (Zecchinon et al., 2005, 
Gyles, 2004). In 1990, all members of biotype T were reclassified as a different 
species called Pasteurella trehalosi which was again reclassified in a new genus 
as Bibersteinia trehalosi following 16S rRNA gene sequencing classification 
(Quinn, 2011, Blackall et al., 2007). In 1999, serotypes of P. haemolytica biotype A 
were reclassified into Mannheimia haemolytica except for serotype A11 which was 
included in the same genus but classified as Mannheimia glucosida (Gyles, 2004, 
Angen et al., 1999). The most common serotypes of M. haemolytica that can 
cause disease are A1 and A2 being A1 prevalence higher in cattle (Singh et al., 
2011, Jaramillo-Meza et al., 2007) while A2 is more common in small ruminants 
(Davies and Donachie, 1996). 
Pasteurella multocida can also cause BRD as a secondary agent but with a lower 
frequency than M. haemolytica. (Dabo et al., 2007). P. multocida is classified in 5 
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serogroups (A, B, C, D, E and F) and 16 serotypes. Serotype A3 is the most 
common isolate in BRD caused by  P. multocida but strains from serogroup  D have 
also been found, particularly in small ruminants (Ewers et al., 2006, Arumugam et 
al., 2011).
Histophilus somni is another Pasteurellaceae member that can produce BRD less 
commonly than M. haemolytica or P. multocida. H. somni does not have a capsule, 
it produces a lipo-oligosaccaride (LOS) that promotes platelet activation causing 
characteristic thrombotic lesions in the pulmonary vessels (Corbeil, 2007, 
Czuprynski, 2009).
Figure 1. Pathogenesis of BRD. In the presence of adverse environmental factors in addition 
to infection with primary viral agents, bacterial commensals of the upper respiratory tract 
(mainly M. haemolytica) reach the lower respiratory tract. Lung consolidation is caused by 
the accumulation of neutrophils and ROS release due to leukotoxin driven lysis.
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1.1.2 Pathology
The characteristic lesions found in necropsy, when BRD is caused by M. 
haemolytica, are areas of consolidation within lobes or that extend to complete 
lobes. Most commonly, the cranial lobes of the lung are affected with a fibrinous 
bronchopneumonia characterised by the presence of coagulated fibrin, augmented 
thickness of the interlobular septa, oedema and well defined foci of coagulative 
necrosis. As M. haemolytica multiplies, it can extend from the initially infected 
bronchi to the adjacent lobules, cover the whole lobe and infect the pleura 
resulting in an acute fibrinous pleuropneumonia that can cause a rapid death 
(Panciera and Confer, 2010, Rehmtulla and Thomson, 1981). In contrast, when 
BRD is caused by P. multocida, lesions are usually suppurative and abscesses 
may be formed (Dabo et al., 2007).
The pneumonic lesions of BRD are caused by the indirect effect of the leukotoxin 
(LKT), the main virulence factor of M. haemolytica. In the presence of M. 
haemolytica in the lung, chemoattractant factors such as IL-8 and leukotriene B4 
are produced by the alveolar macrophages that attract neutrophils to the infection 
site. However, LKT produces lysis of the neutrophils by  small pore formation that is 
specific to ruminant leukocytes. Neutrophil lysis translates into the release of more 
chemoattractants that causes an exaggerated infiltration of neutrophils and 
macrophages, obstructing the alveoli and damaging the tissue due to released 
ROS (Maxie and Jubb, 2007).
The microscopic appearance of affected tissue is characterised by foci of 
coagulative necrosis in which the alveolar space is blocked by the presence of 
coagulated fibrin, neutrophils and macrophages in addition to necrotic leukocytes 
marking the limits of the foci (Maxie and Jubb, 2007). 
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1.1.3 Prevention and treatment
Treatment with antibiotics is generally  effective to control the disease and limit the 
extension of the lesions in the lung. A  study by Schneider et al. showed that 
carcass quality can be maintained at a good level despite infection when animals 
received treatment (Schneider et al., 2009). A review on methods to control BRD 
published by Edwards T.A., emphasises the importance of eliminating the external 
factors that predispose BRD by primarily improving animal housing and farming 
practices (Edwards, 2010). They also describe a procedure known as 
metaphylaxis, in which animals at high risk of developing BRD (Such as animals to 
be shipped or just received) are mass medicated to prevent an outbreak. Typical 
antimicrobials used include cephalosporines, florfenicol, tetracyclines, macrolides 
and tulathromycin (Edwards, 2010). However, there are various studies that 
independently  have isolated field strains of M. haemolytica and P. multocida which 
are resistant to most of the previously  mentioned antimicrobials (Sarangi et al., 
2015, Rainbolt et al., 2016, Klima et al., 2014). Therefore antimicrobial usage 
should be reduced and prevention of the disease must be prioritised.
1.1.3.1 Vaccination
Most vaccines that are commercially available worldwide, are based on the 
chemical inactivation of M. haemolytica, P. multocida and Histophilus somni. 
These mixtures mainly contain killed M. haemolytica cultures made with the most 
common serotypes that cause disease in cattle and domestic small ruminants 
such as A1, A2 and A6. Additionally, in order to provide an immune response 
against LKT, cultures are grown at conditions that increase expression of the toxin 
(Jaramillo-Meza et al., 2007). The use of bacterin-toxoid mixtures can reduce 
6
morbidity  and mortality  however, the response is specific not only to the capsular 
serotype but also to the different alleles of LKT (Lacasta et al., 2015).
In order to produce an immunogen that can protect in a less specific way, various 
studies have been performed. Gilmour et al (Gilmour et al., 1991) developed a 
vaccine, which is currently available in Europe as Bovipast®. It is based on the 
immune response against the iron regulated proteins (IRP) produced by M. 
haemolytica. Their vaccine contains IRP from serotypes A1, A2, A6 and A7, 
providing increased cross protection against other serotypes compared to other 
vaccines (Gilmour et al., 1991, Lacasta et al., 2015).
A live vaccine was developed by making a truncation in the lktA gene to 
genetically  inactivate and attenuate a serotype A1 strain. Vaccination with this 
mutant provided protection against serotype A1 and A6 after challenge (Crouch et 
al., 2012). Live attenuated vaccines are currently licensed and available in the 
USA as Once PMH®.
Finally, there are studies focused on outer membrane antigens with promising 
results. Confer and Ayalew studied the protein PlpE which is highly conserved 
among the different serotypes of M. haemolytica (Ayalew et al., 2006), they 
identified the neutralising epitopes and made a fusion protein with the neutralising 
epitope of LKT that induced the production in mice of antibodies that neutralised 
LKT activity  in vitro (Ayalew et al., 2008). Additionally, intra-nasal vaccination in 
calves provided antibody protection against challenge with M.haemoltica 
serotypes A1 and A6 (Ayalew et al., 2009).
1.2 Mannheimia haemolytica
M. haemolytica is a Gram negative bacterium with a rod or cocobacillus shape, it 
is a facultative anaerobe that normally inhabits the upper respiratory tract of 
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ruminants as a commensal. It is non-motile, it produces β-haemolysis and it is 
surrounded by a capsular polysaccharide which is the basis for serotyping (Lo et 
al., 2001, Quinn, 2011, Gyles, 2004).
1.2.1 Virulence factors
1.2.1.1 Capsule
The capsular polysaccharide of M. haemolytica is known to be a protective factor 
against the immune system by reducing neutrophil and alveolar macrophage 
phagocytosis, conferring protection against complement mediated lysis and 
reducing exposure of protein antigens (Chae et al., 1990, Czuprynski et al., 1991, 
Lindhout et al., 2013). The capsule also promotes adhesion to the respiratory 
epithelium which aids colonisation (Singh et al., 2011, Gyles, 2004, Quinn, 2011).
The difference between capsules of serotypes A1 and A2 is that the 
polysaccharide of A1 is formed by N-acetylmannosaminuroic acid (ManNAcA) and 
N-acetylmannosamine (ManNAc) (Lo et al., 2001, McKerral and Lo, 2002, Adlam 
et al., 1984) while serotype A2 has a polysialic acid capsule (Solana et al., 2001, 
Lindhout et al., 2013).
1.2.1.2 Outer membrane proteins
Several outer membrane proteins (OMP) of M. haemolytica have been identified 
as immunogens exhibited on the surface that are important for bacterial adherence 
and colonisation of the respiratory  tract (Pandher et al., 1999). For instance, 
OmpA is an OMP that has been proven to be important for adherence of M. 
haemolytica to the respiratory epithelium (Kisiela and Czuprynski, 2009) by 
binding to the cell-surface fibronectin (Confer and Ayalew, 2013). Animals that 
recover from BRD and vaccinated animals, usually have high titers of anti-OmpA 
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antibodies (Mahasreshti et al., 1997). Additional data has shown allelic variations 
in OmpA isolated from bovine and ovine strains of M. haemolytica, suggesting a 
role of OmpA in species specificity (Davies and Lee, 2004, Hounsome et al., 
2011). Finally, a recent study showed that bovine apolactoferrin has a bactericidal 
effect on M. haemolytica by binding to OmpA (Samaniego-Barron et al., 2016).
Adhesion to the respiratory  epithelium is also aided by the adhesin MhA which 
recognises N-acetyl-D-glucosamine residues (Jaramillo et al., 2000). Additionally, 
MhA can bind to a GlcNAc rich receptor expressed by neutrophils that stimulates 
oxidative burst (De la Mora et al., 2006, De la Mora et al., 2007).
The lipoprotein PlpE, is another important OMP that has been studied as a 
vaccine candidate due to its conservation and high immunogenicity via 
complement activation (Ayalew et al., 2006, Pandher et al., 1998, Ayalew et al., 
2009, Confer et al., 2009, Batra et al., 2016).
1.2.1.3 Endotoxin: Lipopolysaccharide (LPS)
Similar to other Gram negative bacteria, the LPS of M. haemolytica is formed by a 
polysaccharide side chain or O antigen, a lipid A and inner and outer cores of 
oligosaccharides (Singh et al., 2011). The LPS plays an important role in the 
pathogenicity  of M. haemolytica by activating the coagulation cascade, promoting 
platelet activation, activating macrophages and inducing the production of tumour 
necrosis factor α (TNF-α) which translate into thrombus formation, oedema and 
acute inflammation (Gyles, 2004, Songer and Post, 2005).
1.2.1.4 Leukotoxin
The leukotoxin is a small pore-forming toxin, member of the RTX family of toxins 
that contain characteristic repeats of the motif GGXGXDXUX (X=Any amino acid, 
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U=Large hydrophobic amino acids, i.e. L/V/I/F/Y). RTX toxins are codified in an 
operon formed by four genes: CABD (Linhartova et al., 2010, Chenal et al., 2015). 
The gene lktA codifies the leukotoxin structural protein LktA, which contains the 
RTX motifs, also known as calcium binding motifs. Calcium ions are known to be 
required for the cytotoxic activity of RTX toxins and for appropriate folding of the 
motifs (Chenal et al., 2009). 
RTX toxins are synthesised as protoxins that are activated by a post-translational 
acylation of internal lysine residues. It is thought that acylation is required to 
increase the hydrophobicity of the protein and form the small pores (Zecchinon et 
al., 2005). Even though LktA goes through the acylation step  thanks to the 
acyltransferase LktC, recent experiments have shown that inhibition of acylation 
diminished LktA cytotoxicity but does not abolish it completely (Batra et al., 2015).
Secretion of RTX toxins is performed via the type I secretion system (TISS) in 
which 3 main components are involved: an ATP-binding cassette exporter (ABC 
transporter) that forms a complex with a membrane fusion protein (MFP) and an 
outer membrane protein codified in the bacterial chromosome. The ABC 
transporter of Lkt is encoded by lktB and the MFP is encoded by lktD (Delepelaire, 
2004, Tseng et al., 2009).
The leukotoxin of M. haemolytica has specific cytotoxicity  on ruminant leukocytes 
by specific attachment to β2 integrins of ruminant origin on the CD18 fraction. β2 
integrins are formed by the β subunit CD18 and a variable α subunit that can be 
CD11a (CD11a/CD18 or LFA-1), CD11b (CD11b/CD18 or Mac-1), CD11c (CD11c/
CD18 or CR4) or CD11d (Dileepan et al., 2005a, Dileepan et al., 2005b, 
Dassanayake et al., 2007a, Dassanayake et al., 2007b). Primary infection with 
BHV-1 has been reported to enhance the effects of LKT by enhancing expression 
of BoLFA-1 in infected PMN and PBMCs (Leite et al., 2002, Leite et al., 2005).
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Even though the leukotoxin of M. haemolytica is an important component of the 
vaccines used against BRD, the sequence of the leukotoxin proteins is highly 
variable. Davies et al identified the variable regions in the sequence and classified 
the different alleles into 8 allelic groups of lktA (Davies et al., 2001, Davies et al., 
2002). 
1.2.1.5 Iron regulated proteins (IRP)
Donachie et al (Donachie and Gilmour, 1988) described that when M. haemolytica 
is grown in media with limited concentrations of iron, two immunogenic proteins 
are expressed and now are the basis for the commercial vaccine Bovipast®. A 
35kDa IRP was characterised as FbpA, which is known to be part of the iron 
uptake system FbpABC (Lainson et al., 1991, Kirby et al., 1998)
1.2.1.6 Neuraminidase
M. haemolytica is known to produce an extra-cellular neuraminidase in vitro and 
during active pneumonic infection in cattle and small ruminants (Straus and Purdy, 
1994, Straus et al., 1998). The biological role of the neuraminidase produced by 
M. haemolytica has not been confirmed but it is possible that it aids colonisation of 
the respiratory epithelium, similarly to other respiratory  pathogens such as 
Streptococcus pnuemoniae in humans (Singh et al., 2011).
1.2.2 Immune response to M. haemolytica infection
The alveolar macrophages secrete IL-8, IL-β, TNF-α, GROα, ENA, platelet-
activating factor and leukotriene B4 in response to LPS and LKT (Yoo et al., 
1995a, Yoo et al., 1995b). Neutrophil recruitment is then mediated by IL-8, a 
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neutrophil chemoattractant and activator that stimulates oxydative burst and 
phagocytosis (Caswell et al., 1999, Meade et al., 2012).
Recent reports showed that Th17 and γδ T cells respond to M. haemolytica and 
BRSV co-infection by the augmented expression of IL-17, IL-21 and IL-22 which 
increase the secretion of IL-8 and therefore, increase neutrophil recruitment 
(McGill et al., 2016).
1.3 Neuraminidases
Neuraminidases, also known as sialidases, are a family of enzymes found in 
eukaryotic cells, bacteria, protozoa and viruses that cleave terminal sialic acids 
from oligosaccharides, glycoproteins or glycolipids present on the surface of 
mammalian cells (Taylor, 1996). 
1.3.1 Sialic acids
Sialic acids are a family of 9 carbon acidic terminal monosaccharides bound on 
C-2 by an α-ketosidical link to C-3 or C-6 of a sugar residue (α2-3-, α2-6- linkages) 
(Figure 2). In some molecules, more than one sialic residue can be bound to a 
glycan by an α2-8- linkage to form an oligosialic acid or a polysialic acid (Varki, 
1992, Varki and Schauer, 2009). 
Depending on the group bound to C-5, sialic acids can be divided into four types: 
N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), 
deaminated neuraminic acid (KDN) and de-N-acylated neuraminic acid (Neu) 
(Varki, 1992, Varki and Schauer, 2009).
Neu5Ac is the most common sialic acid, it is present on all mammalian cell 
surfaces and it is also produced by  invertebrates, bacteria and fungi. It contains a 
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CH3-COHN- group bound to C-5 and a hydroxyl group bound to C-2 in the free 
form (Angata and Varki, 2002).
Biologically important molecules present in mammals that contain sialic acid 
residues include mucins, immunoglobulin A, lactoferrin and sialo-oligosaccharides 
found in milk. 
Mucins are highly  sialylated glycoproteins produced by goblet cells on mucosal 
surfaces to lubricate and form a barrier that traps external particles (Lewis and 
Lewis, 2012). The glycocalix of endothelial cells of pulmonary arteries and 
microvascular vessels also contains abundant sialylated glycoproteins that keep 
the integrity of the endothelium (Cioffi et al., 2012). For that reason, colonisation 
by various respiratory pathogens might be influenced by the expression of 
neuraminidases.
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Figure 2. Structure of Neu5Ac derivatives obtained from Pubchem. Free Neu5Ac (CID: 
444885) is bound to a hydroxyl group on C-2 while the inhibitor DANA (CID: 65309) is 
unsaturated. The α-ketosidical linkages 2,3 and 2,6 are depicted by α(2,3)-Sialyllactose (CID: 
9963744) and α(2,6)-Sialyllactose (CID: 9963743) respectively. 
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1.3.2 Neuraminidases as virulence factors
Cleaving terminal sialic acids has proved to be a determinant factor in the onset of 
respiratory  disease. The influenza virus type A and B exhibit different types of 
neuraminidases in a tetrameric haemagglutinin-neuraminidase (HN) complex. 
Sialidase activity  is important for preventing aggregation of newly formed viral 
particles and for cleaving Neu5Ac from mucin of mucosal surfaces to reach their 
target cells (Shtyrya et al., 2009). In BRD, BPI-3 virus is also known to exhibit HN 
(Ellis, 2010). Bacterial species can produce sialidases for using sialic glycans as 
carbon source, to reveal glycoproteins and glycolipids that are targeted by toxins 
or to remove mucin and facilitate colonisation (Taylor, 1996, Kim et al., 2011).
1.3.3 Structure of neuraminidases
The sequence of neuraminidases can be highly variable but they  all share the 
catalytic domain structure. For instance, the neuraminidase of influenza virus type 
A and B only share 30% of identity but their secondary and tertiary structure are 
identical (Shtyrya et al., 2009).
The typical tertiary structure of all neuraminidases consists of a propeller-like 
structure, known as β-propeller, formed by 6 antiparallel β-sheets with 4 strands 
each that surround the site where the substrate is cleaved (Taylor, 1996) (Figure 
3). Neuraminidases can exist as monomeric molecules, such as the 
pneumococcal neuraminidases (Gut et al., 2011), or as multimeric molecules like 
the influenza neuraminidase which forms a tetramer (Shtyrya et al., 2009).
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Figure 3. Tertiary structure of (A) neuraminidase of influenza virus A (PDB: 1NN2) (Varghese 
and Colman, 1991), (B) T.rangeli TrSA (PDB:1MZ5) (Buschiazzo et al., 2000), (C) 
S.pneumoniae NanA (PDB:2YA4) (Gut et al., 2011) and (D) NanB (PDB: 2VW0) (Xu et al., 
2008).
1.3.4 Bacterial neuraminidases
The sequence of bacterial neuraminidases has been reported to show 30% 
identity between species, particularly due to the variability  on their adjacent 
domains. However, they all share two types of motifs that can be considered the 
bacterial sialidases molecular signatures (Taylor, 1996). The first one is the RIP/
RLP motif which contains one arginine that directly interacts with the substrate. 
The second one is the Asp-box motif or bacterial neuraminidase repeats (BNR) 
(Xu et al., 2008) formed by  Ser/Thr-X-Asp-[X]-Gly-X-Thr-Trp/Phe (X=any amino 
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acid), they are found between 1 to 5 times in the sequence of bacterial 
neuraminidases and although they  are known to represent the fold between third 
and fourth strand of the β-sheets of the propeller, additional functions remain 
unknown (Roggentin et al., 1989, Gaskell et al., 1995).
1.3.5 Neuraminidase reaction
Neuraminidases can be classified into three groups according to the type of 
catalytic reaction they perform to cleave sialic residues: Hydrolytic sialidases, 
trans-sialidases and intramolecular trans-sialidases. Interestingly, TrSA is a 
hydrolytic neuraminidase produced by Trypanosma rangeli while TcTS is a trans-
sialidase produced by Trypanosoma cruzi (Amaya et al., 2003, Amaya et al., 
2004). These neuraminidases are closely related as they are both produced by 
trypanosomal species and they show 70% amino acid identity but the substitution 
of just five key residues is sufficient to alter the mechanism of TrSA from hydrolysis 
to trans-glycosylation (Paris et al., 2005, Jers et al., 2014).
Hydrolysis is the most common type of reaction and it is performed by  important 
neuraminidases such as the influenza neuraminidases, the pneumococcal 
neuraminidase NanA and the P. multocida neuraminidases NanH and NanB. The 
catalytic amino acids involved in the reaction and the mechanism are highly 
conserved among hydrolytic sialidases. Based on residue numbering of the 
neuraminidase TrSA, the reaction initiates when a sialylated glycan (Neu5Ac-OR) 
reaches the active site and the carboxylate group formed by C-1 binds to an 
arginine triad formed by Arg36, Arg246 and Arg315. The strong ionic interaction 
between these positively  charged residues and the carboxylic group  of the sialic 
residue, results in a change of conformation of Neu5Ac that allows hydroxylation 
by Asp60 of the O-2 bound to the glycan (HOR). A carbocation is formed on C-2 
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and stabilised by a covalent bond to Tyr343 aided by Glu231, which is believed to 
act as the proton acceptor. Finally, the unstable oxocarbonium is hydroxylated by a 
water molecule resulting in the release of Neu5Ac. Additional interactions include 
positioning of the C-5 bound N-acetyl chain into a hydrophobic pocket formed by 
Met96, Phe114, Trp121 and Val177. (Taylor and von Itzstein, 1994, Shtyrya et al., 
2009, Buschiazzo et al., 2000).
The second group of neuraminidases is known as trans-sialidases. In this reaction, 
Neu5Ac is transferred to a different sugar by a trans-glycosilase reaction in which 
the oxocarbonium is hydroxylated by an acceptor sugar. The products are a 
hydroxylated donor glycan (HOR) and a sialylated acceptor sugar (Neu5Ac-OR’). 
Typically, trans-sialidases are specific to α2-3- bonds (Amaya et al., 2003, Amaya 
et al., 2004).
Sialidases from the third group are known as intramolecular trans-sialidases (IT), 
also have specific cleavage to α2-3- linked sialic acid and react by  trans-
glycosilation. In this reaction, the oxocarbonium is attacked by the hydroxyl group 
bound to C-7, resulting in a covalent bond between C-2 and O-7 therefore, 2,7-
anhydro-NeuAc is released as a product from this reaction instead of Neu5Ac (Gut 
et al., 2011, Xu et al., 2011).
1.3.6 Neuraminidases produced by Pasteurellaceae
In addition to M. haemolytica, neuraminidase activity has been demonstrated in 
other members of the family Pasteurellaceae that include P. multocida 
(Scharmann et al., 1970), Avibacterium gallinarum, A.volantium (Hinz and Muller, 
1977, Muller and Mannheim, 1995) and Haemophilus parasuis (Lichtensteiger and 
Vimr, 1997).
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Regarding secondary  agents that produce BRD, neuraminidase activity of M. 
haemolytica was reported and an exo-sialidase has been purified from culture 
supernatants (Straus et al., 1993a). Neuraminidase activity was also reported in P. 
multocida and an exo-sialidase was also purified from culture supernatants (White 
et al., 1995). Later, Mizan et al reported that P. multocida produces two 
neuraminidases: NanH and NanB (Mizan et al., 2000). Lichtensteiger and Vimr 
evaluated the possible sialidase activity of various members of the 
Pasteurellaceae family including H. somni however, they reported no activity from 
the clinical isolate that they tested (Lichtensteiger and Vimr, 1997).
1.3.6.1 Neuraminidases in P. multocida
The first report of the purification of a neuraminidase from P. multocida was 
obtained from culture supernatants by White et al however, when Mizan et al 
performed their experiments to isolate NanH and NanB, they were only able to see 
neuraminidase activity in cell lysates (White et al., 1995). The sequence analysis 
of NanB shows the typical structure of a protein secreted via type V secretion 
system (TVSS) due to the presence of a putative signal sequence on the N-
terminus and a β-barrel domain on the C-terminus suggesting that it might be 
possible to find NanB in culture supernatants. Even though, the sequence of NanH 
did not show homology to known autotransporters, the predicted secondary 
structure showed the typical arrangement of 14 β-sheets that can form a β-barrel, 
a molecular signature and a signal peptide on the N-terminus (Mizan et al., 2000).
Both neuraminidases of P. multocida were able to cleave α2-3- and α2-6- linked 
Neu5Ac by hydrolysis with preferential activity on α2-3- linkages. However, NanB 
had a higher enzymatic speed on α2-6- linkages than NanH. None of them have 
shown activity on α2-8- bound Neu5Ac (Mizan et al., 2000).
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1.3.7 Neuraminidase produced by M. haemolytica 
Early reports of the neuraminidase produced by  M. haemolytica, mention the 
production in vitro being mainly  observed in bacterial lysates and, to a lesser 
extent, in culture supernatants (Scharmann et al., 1970, Frank and Tabatabai, 
1981). However, extracellular production was confirmed by Straus et al (Straus et 
al., 1993b) when they concentrated the culture supernatant of a serotype A1 
isolate of M. haemolytica and purified a sialidase with a molecular weight between 
150 - 200kDa. In addition, they  showed the presence of neutralising antibodies 
obtained from sera of experimentally  infected goats (Straus and Purdy, 1994) and 
naturally infected cattle (Straus et al., 1998).
Neuraminidase activity was thought to be serotype related (Frank and Tabatabai, 
1981). However, the only serotype without activity was A11, which was later 
reclassified as Mannheimia glucosida (Straus et al., 1993a). Therefore, we can 
conclude that all serotypes of M. haemolytica show neuraminidase activity (Singh 
et al., 2011).
When Straus et al isolated the neuraminidase secreted by M. haemolytica, they 
evaluated different substrates that included N-Acetylneuramin lactose, fetuin and 
bovine submaxillary mucin (BSM) concluding that hydrolysis rate decreased in the 
latter. These data suggest that the neuraminidase of M. haemolytica can cleave 
various α-ketosidical linkages such as the α2-6- linkages found in N-
Acetylneuramin lactose, the α2-3- linkages found in fetuin and, in a lower degree, 
terminal sialic acid in BSM which is also α2-3- linked (Straus et al., 1993a).
Finally, the whole genome sequence project published by  Gioia et al reported an 
incomplete gene with the molecular signatures typical of neuraminidases that 
contain a C-terminal β-barrel domain (Gioia et al., 2006). In addition, Fernández et 
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al submitted the sequence of a neuraminidase of M. haemolytica with a 53% 
identity and 69% similarity  to NanH of P. multocida and complete identity to the 
neuraminidase reported by Gioia et al (GenBank accession: EF215852.1) 
(Fernández Martínez, 2007).
1.3.7.1 The role of neuraminidase in the metabolism of sialic acids in M. 
haemolytica
Sialic acid is known to be required for the synthesis of the capsular polysaccharide 
of M. haemolytica by  the formation of α2,8-linked polysialic acid of serotype A2 
capsules (Solana et al., 2001) or can be used to form ManNAc required by 
serotype A1 strains (Lo et al., 2001).
In P. multocida, free Neu5Ac is necessary for the production of CMP-Neu5Ac that 
is used for the sialylation of oligosaccharides such as the polysaccharide 
component of LPS (Thon et al., 2012). P. multocida is thought to obtain Neu5Ac by 
the effect of other bacteria occupying the same niche or by desialylation of 
Neu5Ac bound glycans of the host aided by the production of NanB and NanH 
following the sialic acid metabolism pathway known as scavenging (Steenbergen 
et al., 2005).
In contrast, M. haemolytica is believed to be able to synthesise Neu5Ac from 
ManNAc by a de novo pathway (Vimr et al., 2004, Barrallo et al., 1999). 
Additionally, M. haemolytica is also able to uptake free Neu5Ac cleaved from the 
host by its own neuraminidase therefore, it might be able to use both mechanisms 
to obtain Neu5Ac (Solana et al., 2001) (Figure 4).
Finally, ManNAc can also be catalysed into fructose-6-phosphate which can be 
used as an energy source through glycolysis (Severi et al., 2007, Ferrero and 
Aparicio, 2010, Li and Chen, 2012).
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Figure 4. Diagram of proposed sialic acid metabolism based on metabolic pathways of E. 
coli (Severi et al., 2007, Ferrero and Aparicio, 2010, Li and Chen, 2012) and experimental 
data on M. haemolytica  published by Lo et al (Lo et al., 2001), McKerral (McKerral and Lo, 
2002) et al and Barrallo et al (Barrallo et al., 1999). Neu5Ac = N-Acetylneuraminic acid, 
ManNAc = N-Acetylmannosamine, ManNAcA = N-Acetylmannosaminourate, GlcNAc = N-
Acetylglucosamine, Fru = Fructose, PEP = Phosphoenol piruvate, CPS = Capsule, PST = 
Polysialyl transferase,  NeuC-like = UDP-N-acetylglucosamine-2-epimerase (Similar to NeuC 
of E. coli), NmaA = UDP-N-acetylglucosamine-2-epimerase, NmaB = UDP-N-
acetylmannosamine dehydrogenase.
1.3.8 Neuraminidases of Streptococcus pneumoniae, a respiratory disease 
comparative model
S.pneumoniae produces 3 neuraminidases: NanA, NanB and NanC. All 
pneumococcal strains have a nanA gene, nanB is present in ~96% and nanC is 
only present in ~50% of strains (Pettigrew et al., 2006).
They share a similar structure which consists of a signal peptide at the beginning 
of the sequence, a lectin-like binding domain or carbohydrate binding module 
(CBM) which increases activity  by recognising sialic acid (Xu et al., 2008), a 
catalytic domain which contains 4 Asp-box repeats and a third domain inserted 
into the catalytic domain. Additionally, NanA has a fourth domain which contains a 
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motif formed by  Leu-Pro-Glu-Thr-Gly  that attaches the enzyme to the bacterial 
membrane known as LPXTG anchor motif (Xu et al., 2008, Camara et al., 1994, 
Hsiao et al., 2009).
NanA catalyses sialic acid by  hydrolysis cleaving either α2-8-, α2-3- or α2-6- 
linked sialic acid into Neu5Ac while NanB is an IT so it reacts by trans-glycosilation 
strictly on α2-3- bonds producing 2,7-anhydro-NeuAc (Xu et al., 2008, Gut et al., 
2008). NanC has been reported to cleave α2-3- linkages and catalyse into 2-
deoxy-2,3-dehydro-N-acetylneuraminic acid (Nau5Ac2en or DANA) which is a 
sialidase inhibitor but after the accumulation of this product, NanC is able to then 
hydrate it into Neu5Ac. The molecular weight of NanA, NanB and NanC is 115kDa, 
78kDa and 82kDa respectively (Xu et al., 2011, Hayre et al., 2012).
1.3.8.1 Role of desialylation in pneumococcal infection
Bacterial neuraminidases have been related to colonisation depending on the 
agent that produces them and the site of the disease. In cases like Vibrio cholerae 
infection, neuraminidase is crucial in the pathogenesis of disease since 
desialylation of host glycoconjugates reveals a toxin receptor (Corfield, 1992, 
Taylor, 1996).
Pneumococcal neuraminidases have different roles in colonisation and onset of 
infection depending on the site of S.pneumoniae interaction with the host. 
Desialylation of glycoconjugates in host cells and competing bacteria has been 
proposed as an important mechanism of adherence since S.pneumoniae produces 
other 2 surface exoglycosidases that may act consecutively after neuraminidases 
to effectively reveal adherence factors by deglycosylation (King et al., 2006, 
Kadioglu et al., 2008). Previous work has demonstrated that the presence of 
NanA and NanB increases colonisation and onset of infection in lower and upper 
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respiratory  tract (Manco et al., 2006, Brittan et al., 2012) with an additional 
interaction being proposed which is the usage of sialic acid as a carbon source for 
bacterial growth (Burnaugh et al., 2008, Marion et al., 2011).
The role of desialylation by  pneumococcal neuraminidases has not only been 
studied in the respiratory  tract but in other models of pneumococcal infection with 
particular attention to its ability to reveal receptors. In the blood stream, platelets 
expose glycoconjugates susceptible to desialylation that are recognised by  the 
Ashwell-Morell receptor in hepatocytes for elimination which results in moderation 
of the severity  of disseminated intravascular coagulation (Grewal et al., 2008, 
Grewal et al., 2013).
Neuraminidase activity on PBMC causes augmented TLR exposure provoking 
exacerbated injury caused by  their ligands such as increased recruitment of 
PMNs, induction of TNF-α, IL-1β and chemokines caused by LPS association with 
TLR4 (Feng et al., 2012, Feng et al., 2013).
In pneumococcal haemolytic uraemic syndrome, NanA removes terminal sialic 
acid from glycoproteins in red blood cells revealing an antigen called Thomsen-
Friedenreich antigen or T-antigen that is recognised by IgM antibodies causing 
erythrocyte agglutination and lysis (Loirat et al., 2012, Mele et al., 2014, Coats et 
al., 2011, Smith et al., 2013) .
Neuraminidases have been associated with pneumococcal biofilm formation. 
Parker et al showed that the inhibition of neuraminidase activity  in vitro reduces 
biofilm formation (Parker et al., 2009). Upregulation of nanA and nanB has also 
been reported in biofilm models in vitro, particularly  in the presence of sialic acid in 
the media (Trappetti et al., 2009, Oggioni et al., 2006).
Although research on neuraminidase has not primarily focused on its use as a 
vaccine, studies have shown that immunisation of chinchillas with NanA prevents 
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colonisation of the upper respiratory tract and middle ear therefore, by 
investigating colonisation increase in the otitis media model, more evidence was 
provided to support colonisation hypotheses (Long et al., 2004, Tong et al., 2005).
1.3.8.2 Desialylation-independent interaction of neuraminidases in pneumococcal 
infection
Studies on pneumococcal meningitis have shown that neuraminidases play an 
important role in blood-brain barrier adherence increasing colonisation due to a 
possible interaction of the lectin-like domain rather than desialylation (Uchiyama et 
al., 2009), as a result, NanA induces chemokine production and neutrophil 
recruitment (Banerjee et al., 2010). 
1.3.9 Inhibitors of neuraminidases
Current inhibitors of sialidases that were developed as a treatment for influenza 
virus infection are based on the natural inhibitor DANA, an analogue of the 
transition state of Neu5Ac formed during hydrolysis. As shown in figure 2, C-2 of 
DANA is unsaturated therefore, it can form strong bonds to the catalytic site of 
neuraminidases without cleavage. Even though DANA is unable to block sialidase 
activity  in vivo, it was used as a molecule backbone for designing the worldwide 
licensed antivirals zanamivir and oseltamivir. A  problem that has to be tackled in 
the field of influenza research, is the quick mutation rate of the virus that has led to 
resistance to both antivirals in most of the seasonal strains. Newer neuraminidase 
inhibitors have been recently developed such as peramivir and lanamivir. 
Peramivir is currently licensed in the USA, Japan and Korea while lanamivir is only 
licensed in Japan (Yen, 2016, Air, 2012).
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The viral neuraminidase inhibitors have been tested against pneumococcal 
neuraminidases in the hope of providing an added benefit to antivirals on a 
secondary infection with S.pneumoniae. Zanamivir and oseltamivir can partially 
inhibit activity of NanA compared to inhibition of the influenza neuraminidases (Gut 
et al., 2011). Treatment with oseltamivir resulted in augmented survival of 
experimentally infected mice (McCullers, 2004). Recently, Xu et al associated the 
high variability  of NanA sequence to activity  inhibition, showing that variations in 
the inserted domain and the lectin-like binding domain influence the susceptibility 
of NanA to neuraminidase inhibitors (Xu et al., 2016).
1.4 Type V secretion system
The sequences of the neuraminidases produced by P. multocida and M. 
haemolytica suggest secretion via type V secretion system (TVSS) (May et al., 
2001, Gioia et al., 2006). Therefore, it is important to understand how this system 
works. The general structure of a protein secreted via TVSS contains an N-
terminal signal sequence followed by  a passenger domain, a linker sequence and 
a C-terminal β-barrel domain. There are five proposed subclasses of 
autotransporter mechanisms known as type Va, Vb, Vc, Vd and Ve. The general 
secretion mechanisms start by expression of the unfolded protein in the cytoplasm 
and transport to the periplasmic space via Sec system. Once in the periplasm, the 
signal peptide is cleaved off (Henderson et al., 2004, Leo et al., 2012).
The following steps vary depending on the type of autotransporter. The classical 
mechanism or type Va is typical of proteins such as the IgA protease of Neisseria 
meningitidis, EspP produced by E. coli, pertactin and BrkA, both produced by 
Bordetella pertussis (Leo et al., 2012). In this type of autotransporter, the 
chaperones Skp, FkpA, SurA and DegP prevent folding of the protein. The BAM 
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complex then recognises a conserved C-terminal motif (Robert et al., 2006) and 
the β-barrel inserts into the outer membrane. Two models of translocation have 
been proposed. In the hairpin model, the unfolded passenger domain is thought to 
be translocated into the extracellular space through the β-barrel while the second 
model suggests translocation through the BamA β-barrel. Both models propose 
that folding takes place after secretion although misfolded proteins may be present 
in the periplasmic space but they get degraded by DegP (Leyton et al., 2012). The 
passenger protein can remain attached to the β-barrel as a membrane associated 
protein or may be cleaved by asparagine cyclisation due to the interaction of an 
aspartate in the β-barrel that binds to an asparagine in the linker domain (Dautin et 
al., 2007, Barnard et al., 2007, Barnard et al., 2012).
Secretion system type Vb, also known as the two-parter secretion pathway, is 
transported through the outer membrane via a β-barrel however, the passenger 
domain (TpsA) and the β-barrel (TpsB) are expressed as independent proteins 
that recognise each other by a TPS domain in TpsA that interacts with a POTRA 
domain in TpsB (Henderson et al., 2004, Leo et al., 2012). In type Vc secretion, 
the β-barrel is thought to be a trimeric structure formed by the C-terminus domain 
of three molecules forming a single channel (Henderson et al., 2004). Type Vd is a 
recently described mechanism that resembles a combination between type Va and 
Vb as a single protein contains a passenger and a β-barrel domain but a POTRA 
domain is present between them. Type Ve is a suggested mechanism that acts in 
the same way as type Va however, the position of the domains is inverted 
therefore, the β-barrel is formed by the N-terminal domain and the passenger 
domain is on the C-terminus (Leo et al., 2012).
The functionality of TVSS in M. haemolytica has not been confirmed however, 
genome sequence analysis shows that M. haemolytica might produce two IgA 
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peptidases that contain a pertactin-like type Va autotransporter domain and two 
genes codifying for two YadA-like autotransporters that possibly form a trimeric 
pore typical of type Vc autotransporter (Gioia et al., 2006). Additionally, Daigneault 
and Lo showed the formation of Ahs trimmers, a protein suspected to form YadA-
like β-barrel structures (Daigneault and Lo, 2009). The specific serotype 1 antigen 
(SSA-1) is an outer membrane protein that has been studied as a vaccine 
candidate (Lo et al., 1991, Ayalew et al., 2011) and it is also believed to be 
exported by  TVSS due to its similarity  to the group of the subtilase 
autotransporters (Henderson et al., 2004). The genome sequence of P. multocida 
also shows YadA and pertactin like autotransporters that have not been confirmed 
to be functional either (May et al., 2001).
Neuraminidases produced by  both P. multocida and M. haemolytica are believed 
to be exported via TVSS due to the presence of all the autotransporter 
components in their sequence (Gioia et al., 2006, Mizan et al., 2000) however, the 
functionality of their autotransporter domain has not been confirmed.
1.5 Conclusion
Despite current efforts to eliminate BRD by  treatment and prophylaxis, the disease 
still causes important economic losses for bovine, ovine and caprine producers 
due to mortality and reduction of carcass quality. 
Neuraminidase has been poorly studied in M. haemolytica however, it might play 
an important role in colonisation, infection and metabolism. Therefore, by 
identifying the major structural moieties of the M. haemolytica neuraminidase we 
can propose this protein as a target for either treatment or prevention of BRD.
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1.6 Aims of the project
Identify  genes involved with the M. haemolytica neuraminidase that can provide 
information about the biological role of the enzyme. Clone and purify recombinant 
M. haemolytica NanH. Characterise the catalytic site of NanH to identify potential 
inhibition targets that can be studied in depth for future treatment and prophylactic 
strategies.
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2 Materials and methods
2.1 Bacterial strains
Two of the strains of Mannheimia haemolytica used in this study were obtained 
from ATCC via LGC standards, UK in a lyophilised form. A sample was streaked 
from the pellets into 5% sheep blood agar and incubated at 37ºC  for overnight. 
One colony of each strain was transferred to 10ml of brain heart infusion (BHI) and 
incubated at 37ºC with shaking for overnight. Cultures were centrifuged at 3000 x 
g for 10 minutes, the supernatant was discarded and the pellet was resuspended 
in BHI + 15% glycerol for storage at -80ºC.
The first strain obtained from ATCC was strain PHL213 also known as SH789 or 
ATCC BAA-410. It is a serotype A1 strain originally isolated from the lung of a 
bovine with pneumonia (Fedorova and Highlander, 1997, Highlander et al., 2000) 
and it was first genome sequenced (Accession no. AASA00000000.1) by Gioia et 
al (Gioia et al., 2006).
The second strain is the type strain NCTC 9380 or ATCC 33396, originally isolated 
in the UK in 1956. It is a serotype 2 strain that was used by Angen et al for the 
reclassification of Pasteurella haemolytica into Mannheimia haemolytica by 16S 
rRNA sequencing (Angen et al., 1999).
2.2 Genomic DNA isolation
Strain 33396 was grown from the previously made glycerol stock in 5% sheep 
blood agar at 37ºC for overnight. A colony was transferred into 10ml of BHI and 
incubated at 37ºC  with shaking for overnight. The culture was centrifuged at 3000 
x g for 10 minutes, the supernatant was discarded and genomic DNA was isolated 
using the Wizard Genomic DNA Purification Kit (Promega, UK) from the cell pellet.
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Concentration of isolated genomic DNA was measured using the Quant-iT dsDNA 
Assay Kit, broad range (Thermo Fisher Scientific, UK). Fluorescence was 
measured using the Qubit fluorometer (Thermo Fisher Scientific, UK).
Additionally, genomic DNA from two strains isolated in Mexico was kindly provided 
by Dr José Francisco Morales Álvarez. The strains, identified as MexA1 and 
MexA2, had been serotyped as A1 and A2 respectively. They  are currently  used as 
a source of leukotoxin for producing a toxoid used in immunisation of bovine, ovine 
and caprine calves, manufactured by INIFAP (Instituto Nacional de 
Investigaciones Forestales Agrícolas y Pecuarias) in Mexico.
2.3 Whole genome sequencing
A sample of genomic DNA from strains ATCC  33396, MexA1 and MexA2 was 
submitted to Microbes-NG for whole genome sequencing by the Ilumina MiSeq 
platform. Sequencing of strains MexA1 and MexA2 was still under process at the 
time this work was submitted but the sequence of ATCC 33396 was obtained.
The Microbes-NG facility now has a standard analysis pipeline as follows: to 
identify the closest available reference genome using Kraken, and map the reads 
to this using BWA mem. Variants relative to the reference will be detected using 
freebayes. Concurrently a de novo assembly of the reads is generated using 
SPAdes, and the reads mapped back to the resultant contigs, again using BWA 
mem. The contigs are reordered and reoriented relative to the reference genome 
based on a MUMmer whole-genome alignment, and an automated annotation is 
performed using Prokka (https://microbesng.uk/microbesng-faq/).
However, whilst the facility developed this pipeline WGS data was analysed within 
the research group by Dr A. Mitchell. The raw data was downloaded as fastq files 
and both reference and de novo assemblies were performed on each data set 
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using the assembly functions of the CLC  Genomics Workbench software package 
v9 (Qiagen - https://www.qiagenbioinformatics.com/products/clc-genomics-
workbench/). Automated annotation was performed by submitting draft assemblies 
for Rapid Annotation using Subsystem Technology at http://rast.nmpdr.org/ 
(Overbeek et al., 2014).
2.4 Sanger sequencing
The sequence of nanH of strains PHL213, MexA1 and MexA2 were amplified by 
PCR using MyTaq PCR mix (Bioline, UK) by  preparing the following mix and 
optimising to the following thermo cycling conditions:
Component Concentration
2x MyTaq mix 25µl x (n+1)
Primers (10pmol/µl each) 0.5µl x (n+1) (Each)
Water (Molecular grade) Made up to 50µl x (n+1)
n = Number of samples + 1 positive control + 1 negative control.
Table 1 . Concentration of components required for PCR using MyTaq mix.
Step Temperature Time Cycles
Initial denature 95ºC 1min 1
Denature 95ºC 30s
35Annealing 55ºC 30s
Extension 72ºC 1min
Final extension 72ºC 10min 1
Final hold 4ºC Indefinite
Table 2. Temperature conditions required for PCR using MyTaq mix, M. haemolytica 
genomic DNA as template and primers required for amplification of nanH.
A 5µl sample of each PCR product was diluted in FastDigest green buffer 10x 
(Thermo Fisher Scientific, UK) and loaded on a 1% agarose gel + SYBR Safe 
Stain (Thermo Fisher Scientific, UK) made in TAE buffer. Gel electrophoresis was 
performed at 100V for 25min.
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After confirmation of the presence of a ~2.4kbp band, the amplified reaction was 
cleaned using the Wizard SV Gel and PCR Clean-Up System (Promega, UK).
Sanger sequencing service was provided by The Functional genomics Laboratory 
in the School of Biosciences at the University  of Birmingham (http://
www.birmingham.ac.uk/facilities/genomics/about/sequencing.aspx).
The genomic DNA template was diluted with the appropriate sequencing primer as 
shown:
Component Concentration
DNA template ~100ng
Primer 3.2pmol
Water (Molecular grade) Make up to 10µl
Table 3. Required concentration of DNA sample submitted for Sanger sequencing.
Sequencing results were trimmed depending on peak quality  and aligned against 
the sequence of NanH (EF215852) using software CLC Main Workbench 7 
(Qiagen).
Primer name Sequence
EcoRI-NanH CGCGCGGAATTCAATGAGAAAAATCAA
XhoI-NanH-R CGCGCTCGAGTTACCAGTTATAACTTA
NanH-int-R2 CTTTAATAGTGGCAGCTGG
NanH-int-F2 TCCAGGTTCAGGTAATGCC
NanH-int-F3 GATGTGCGGTTTGAATTG
NanHfl1 CGGAAAAAGGGACAATGGATAACC
NanHfl2 GGGTTATGGGATTGATTATGC
Table 4. Primers used for NanH sequencing.
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2.5 Sequence alignments
Multiple sequence alignments were performed using the tool CLUSTALO (Sievers 
et al., 2011), incorporated as a plugin of the software CLC Main Workbench 7 
(Qiagen).
Results were highlighted for conservation using ESPript 3.0 (Robert and Gouet, 
2014).
2.6 Prediction of functional domains (BLAST)
All protein alignments performed with BLAST were done through the NCBI online 
tool by comparing sequences to non-redundant protein sequences (nr) 
(databases: GenBank CDS translations, PDB, SwissProt, PIR, PRF) using the 
blastp (protein-protein BLAST) algorithm (Marchler-Bauer and Bryant, 2004, 
Marchler-Bauer et al., 2009, Marchler-Bauer et al., 2011, Marchler-Bauer et al., 
2015).
2.7 Predictions of tertiary structure (Phyre2)
Protein tertiary structure was modelled by sequence homology to the coordinates 
of similar proteins with a known tertiary structure that had been previously solved 
by crystallography methods using the server Phyre2 (Kelley and Sternberg, 2009, 
Kelley et al., 2015).
The sequence alignment was retrieved from the table of results provided by 
Phyre2 and results were highlighted for the conservation of primary and secondary 
structure using ESPript 3.0 (Robert and Gouet, 2014).
Tertiary structure models were analysed with MacPymol (Schrödinger). This 
software was used for tertiary structure alignments, identification of active site, 
prediction of enzyme-substrate interactions and for sketching final figures.
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2.8 M. haemolytica cell lysates
M. haemolytica strains 33396 and PHL213 stored at -80ºC  were resuscitated by 
transferring a sample from glycerol stock into 5% sheep  blood agar using a sterile 
plastic loop  and incubating at 37ºC for overnight. One colony of each strain was 
then transferred into 10ml of RPMI 1640 (Sigma, UK) + 3% Foetal bovine serum 
(FBS) (Sigma, UK) and incubated at 37ºC  with shaking for overnight. One millilitre 
of each overnight culture was transferred into 50ml of RPMI 1640 + 3% FBS and 
incubated at 37ºC  with shaking until OD600 reached ~0.6. The cultures were 
centrifuged at 3000 x g for 5 minutes, the pellets were resuspended in 200ml of 
RPMI 1640 +  3% FBS pre-warmed at 37ºC  and incubated for an additional 4 
hours.
Bacterial cultures were centrifuged at 3000 x g for 15 minutes, the supernatant 
was filter sterilised with a 500ml Vacuum filter/storage bottle system, 0.22µm pore 
(Corning, UK) and stored at 4ºC  identified as “Supernatant” or “Sup”. The cell 
pellet was resuspended in 10ml PBS and centrifuged again under the same 
conditions. The pellet was washed in the same way 3 times and resuspended in 
10ml PBS afterwards. Washed pellets were supplemented with 50µl of 25x 
cOmplete EDTA free protein inhibitor cocktail (Roche, UK), 1mM benzamidine 
(Sigma, UK) and 1µg/ml DNAse I (Sigma, UK).
The cell pellet was disrupted in a constant systems cell disrupter at 12KPsi and 
centrifuged at 12000 x g for 25 minutes. The supernatant was filter sterilised with a 
0.2µm pore syringe filter (Millipore, UK) and stored at -20ºC labelled as “Soluble 
lysate” or “Sol”. The pellet was washed in PBS 3 times, resuspended in 10ml of 
PBS afterwards and 1ml was stored at -20ºC labelled as “Insoluble cell debris” or 
“Ins”.
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2.8.1 Concentration of culture supernatants
After filter sterilising the culture supernatants, 100ml from each strain were 
concentrated using an Amicon Ultra-15 Centrifugal filter unit (Millipore, UK) with a 
cut-off point of 100kDa. The flow-throw was subsequently  concentrated with a 
50kDa cut-off point centrifugal filter unit. Concentrate solutes were resuspended in 
500µl and stored at -20ºC. A sample of each fraction was stored at -20ºC in order 
to analyse supernatant fractions smaller than 50kDa, between 50kDa and 100kDa 
and larger than 100kDa.
2.9 Cloning and purification of M. haemolytica NanH catalytic 
domain
2.9.1 Plasmid construction
Plasmid constructs were initially designed in vector pET33b for 6x His-tag 
purification however, when the constructs were made and cloned into E. coli strain 
α-select (Bioline, UK), the random mutation rate was very high. Additionally, when 
a construct with no mutations was obtained and cloned into BL21 (DE3) (NEB, 
UK) for protein expression, no soluble protein was expressed. 
In order to solve both problems, the HaloTag System engineered by Promega was 
used instead. Briefly, protein purification is performed by  fusing the protein of 
interest to a HaloTag for increased solubility. The HaloTag forms a covalent bond 
with the HaloTag resin and it is subsequently cleaved off using a TEV protease. 
The TEV protease is fused to a 6x His-tag so it can be removed by nickel affinity. 
The resulting preparation contains a purified protein without a peptide Tag.
Plasmid constructs were made according to instructions of the manufacturer of 
vector pFN18K (Promega, UK) which is part of the HaloTag System.
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2.9.1.1 PCR amplification
Inserts were amplified by PCR using velocity DNA taq polymerase (Bioline, UK), a 
high fidelity polymerase used to decrease the mutation rate. Reaction mix and 
PCR conditions were prepared as follows:
Component Concentration
5x Hi-Fi Reaction Buffer 10µl
100mM dNTP Mix 0.5µl
DNA template 50-100ng
Primers 10pmol each
Velocity DNA taq polymerase 0.5U
DMSO 1.5µl (Only when template is gDNA) 
Water (Molecular grade) Made up to 50µl per reaction
Table 5. Concentration of components required for PCR using Velocity DNA taq polymerase.
Step Temperature Time Cycles
Initial denature 98ºC 2 min 1
Denature 98ºC 30s
30Annealing 55ºC 30s
Extension 72ºC 15s / kb
Final extension 72ºC 10min 1
Final hold 4ºC Indefinite
Table 6. Temperature conditions required for PCR using Velocity DNA taq polymerase, M. 
haemolytica genomic DNA as template and primers required for amplification of nanH.
PCR products were diluted in FastDigest green buffer 10x (Thermo Fisher 
Scientific, UK) and loaded on a 1% agarose gel + SYBR Safe Stain (Thermo 
Fisher Scientific, UK) made in TAE buffer. Gel electrophoresis was performed at 
100V for 25min.
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The size of the bands was compared to invitrogen 1Kb  Plus DNA Ladder (Thermo 
Scientific, UK). Bands with the expected size were excised from the gel and 
cleaned using Wizard SV Gel and PCR Clean-Up  System (Promega, UK) 
however, DNA was eluted in 25µl in the last step  to increase the concentration in 
the samples. The concentration of the PCR product was calculated using Quant-It 
dsDNA Assay Kit BR and read in Qubit fluorometer.
2.9.1.2 DNA digestion and T4 ligation
Plasmid vector pNF18K and PCR product were digested using the Flexi Enzyme 
Blend (SgfI & PmeI) (Promega, UK) in separate reaction mixes as follows:
Component PCR product digestion Vector digestion
5x Flexi Digest Buffer 4µl 4µl
DNA ~500ng 200ng
Enzyme blend (SgfI and PmeI) 4µl 2µl
Water (Molecular grade) 12µl Make up to 20µl
Table 7. Components required for digestion of PCR product and plasmid vector using 
enzyme blend (SgfI and PmeI).
Reactions were incubated at 37ºC  for 1 hour. Vector digestion mix was incubated 
at 65ºC for 20min for enzyme inactivation and kept on ice until next step. PCR 
product digestion mix was cleaned using Wizard SV Gel and PCR Clean-Up 
system. The concentration of the PCR product was calculated using Quant-It 
dsDNA Assay Kit BR and read in Qubit fluorometer.
Digested PCR product and vector were ligated using T4 DNA Ligase (HC) 
(Promega, UK) by setting the following mix:
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Component Concentration
Digested vector 10µl
Digested PCR product 3µl
T4 DNA Ligase (HC) ~150ng
Water (Molecular grade) Make up to 20µl
Table 8. Components of DNA ligation using T4 DNA ligase (HC) to insert PCR product into 
plasmid vector pFN18K digested by enzymes SgfI and PmeI.
Ligation reaction was incubated for 1 hour at room temperature and cloned into E. 
coli Single Step (KRX) Competent Cells (Promega, UK) by chemical 
transformation. 
2.9.1.3 Chemical transformation into E. coli KRX competent cells
Cells initially stored at -80ºC, were thawed on ice and 50µl were transferred into 
1.5ml microfuge tubes. 5µl of ligation mix were transferred into one of the tubes 
containing thawed cells, additionally, a positive control transformation reaction was 
set with 50ng of pET33bPLY (Made by previous members of the group, this 
plasmid provides kanamycin resistance just as pFN18K) and a negative control 
transformation with 5µl of molecular grade water. Cells with DNA sample were 
incubated on ice for 30min and heat shocked for 20s at 42ºC followed by  a 2 
minute incubation on ice. Heat shocked cells were resuspended in 500µl of SOC 
media and incubated at 37ºC  with shaking for 1 hour. A sample of 100µl was 
transferred to an LB agar plate and a second one of 100µl into an LB plate 
containing 50µg/ml kanamycin. For the control reactions, only 1 plate of plain LB 
and 1 plate of LB + antibiotic were prepared while cells transformed with ligation 
mix were transferred into 1 plain LB plate and 4 plates of LB + antibiotic in order to 
increase the probability of finding a correct plasmid.
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2.9.1.4 Identification of recombinant colonies by PCR
Colonies were analysed by colony PCR using primers 7F and 7G that amplify the 
sequence within the plasmid pFN18K localised between the T7 promoter and T7 
terminator that contains the SgfI and PmeI cloning site in which the PCR product is 
expected to be cloned.
The PCR reaction mix was prepared using Mytaq Mix (Bioline, UK) at the following 
concentrations:
Component Concentration
2x MyTaq Mix 12.5µl x (n+1)
Primers (10pmol/µl each) 0.25µl x (n+1) (Each)
Water (Molecular grade) Made up to 25µl x (n+1)
n = Number of analysed colonies + 1 positive control + 1 negative control.
Table 9. Concentration of components required for PCR using MyTaq mix for colony PCR.
Reaction mix was prepared as a master mix and divided in 200µl microfuge tubes 
depending on the number of colonies to be analysed in addition to 1 positive and 1 
negative control. Using sterile pipette tips, colonies were transferred to each tube 
and then to a plate containing LB agar +  50µg/ml kanamycin with a grid drawn on 
the outside in order to identify each colony properly. The PCR reaction was set in 
a thermo cycler under the following conditions:
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Step Temperature Time Cycles
Initial denature 95ºC 1min 1
Denature 95ºC 30s
30Annealing 55ºC 30s
Extension 72ºC 2min
Final extension 72ºC 10min 1
Final hold 4ºC Indefinite
Table 10. Temperature conditions required for PCR using MyTaq mix, E. coli transformed 
colonies as template and primers required for amplification of the cloning region of pFN18K 
(i.e. 7F and 7G).
The PCR products were analysed by  gel electrophoresis on a 1% agarose gel + 
SYBR Safe Stain as previously described.
Colonies in which it was possible to identify a band with the size of the insert plus 
HaloTag gene, T7 promoter and T7 terminator, were transferred into 10ml of LB + 
50µg/ml Kanamycin by duplicate and incubated at 37ºC with shaking for overnight. 
Obtained cultures were centrifuged at 3000 x g for 10min and supernatant was 
removed. One of the pellets was resuspended into 10ml of LB +  15% glycerol and 
stored at -80ºC while the other one was used for plasmid isolation.
2.9.1.5 Plasmid isolation and analysis by sequencing
Plasmid was isolated using the GeneJET Plasmid Miniprep Kit (Thermo Scientific, 
UK) according to manufacturer instructions but eluted in 25µl of elution buffer in 
order to get a plasmid preparation with a higher concentration.
In order to confirm that the gene of interest was inserted into the vector and no 
unwanted mutations were present, the plasmid was submitted to the Functional 
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Genomics Laboratory  for determination of the sequence by Sanger sequencing. 
The samples were prepared as previously mentioned.
Primer name Sequence
SgfI-NanHG63-F AGGAGCGATCGCCGGTGAAGCTGCAGGTACTGCGCCATTATATT
SgfI-NanHG23-F GACGGCGATCGCCAACTCTGATTTTTGGAAAAGC
PmeI-NanH23-R ACGTGTTTAAACCCAGTTATAACTTACATTTAGACC
PmeI-NanHL435-R ACGTGTTTAAACAAGTTCATCTGGTAATCCCCA
7F TAATACGACTCACTATAGGG
7G GCTAGTTATTGCTCAGCGGTG
pFN18K-seq-F GTCTGAATCTGCTGCAAGA
Table 11. Primers used for cloning procedure.
2.9.2 Protein expression
Expression was controlled with the addition of glucose and rhamnose. The E. coli 
strain KRX contains the rhamnose inducible promoter rhaPBAD that controls the 
expression of T7 RNA polymerase. Additionally, transcription is controlled by  a 
cAMP receptor protein (CRP) which is not activated when glucose is being used 
as a carbon source due to low levels of cAMP (Hartnett et al., 2006).
KRX strain is unable to metabolise rhamnose due to the deletion of rhaBAD 
(replaced by T7 RNA polymerase gene) however, it cannot induce expression until 
glucose has been completely catabolised and cAMP levels have risen.
Bacteria were grown by transferring one colony  into 10ml of LB + 0.5% glucose + 
50µg/ml kanamycin and incubating at 37ºC with shaking for 8-12 hours. A sample 
of 500µl was taken after incubation, centrifuged at 3000 x g for 15min and 
resuspended into 50ml of expression media (LB + 0.05% glucose + 0.05% 
rhamnose +  50µg/ml kanamycin). The 50ml culture was incubated at 28ºC with 
shaking for 20 hours.
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The culture was centrifuged at 3000 x g for 20 minutes, a sample of 1ml was 
taken, filter sterilised and labelled as “Culture supernatant” or “Sup”. The 
remaining supernatant was discarded, cell pellet was afterwards resuspended in 
10ml of PBS, centrifuged at 3000 x g for 10min, supernatant was removed and 
pellet was washed two more times with PBS to complete a total of 3 washes with 
PBS. After the last wash, the cell pellet was resuspended in 10ml of PBS.
Washed cell pellet was supplemented with 50µl of 25x cOmplete EDTA-free 
Protease inhibitor cocktail (Life technologies, UK) + benzamidine +  DNAse I 
(Sigma, UK) and disrupted in a constant systems cell disrupter at 12 KPSI.
Disrupted cells were centrifuged at 20000 x g for 25 minutes, the supernatant was 
filter sterilised and labelled as “Soluble lysate” or “Sol”. The pellet was washed in 
PBS three times and resuspended in 10ml of PBS. A 1ml sample was taken and 
labeled as “Insoluble cell debris” or “Ins”.
2.9.3 Protein purification by HaloTag system
Protein expression was induced as mentioned before however, when cultures 
were made for protein purification, the volumes were increased 10 times. 
Therefore, one colony of E. coli containing the plasmid construct with the 
sequence of the protein of interest was transferred to 10ml of LB + 50µg/ml 
kanamycin + 0.5% glucose, incubated at 37ºC  with shaking for 8-12 hours. A 
sample of 5ml was centrifuged at 3000 x g for 15 minutes, the pellet was 
resuspended in 500ml of LB + 50µg/ml kanamycin +  0.05% glucose + 0.05% 
rhamnose and incubated for an additional 20 hours at 28ºC with shaking.
The culture was centrifuged at 3000 x g for 20 minutes, 1ml of supernatant was 
filtered sterilised and stored for further analysis. Cell pellet was washed three 
times with PBS, supplemented with 1 tablet of EDTA-free Protease inhibitor 
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cocktail (Life technologies, UK) + 1mM benzamidine (Sigma, UK) + 1µg/ml DNAse 
I (Sigma, UK) and disrupted in a constant systems cell disrupter at 12 KPSI.
Cell lysate was centrifuged at 20000 x g for 25 minutes, soluble fraction was filter 
sterilised while insoluble cell debris was washed with PBS three times and 1 ml 
was stored for analysis.
HaloLink Resin (Promega, UK) was centrifuged at 1000 x g for 5min and washed 
three times with HaloTag Protein Purification Buffer (50mM HEPES (pH7.5), 
150mM NaCl) for equilibration using the same centrifuge parameters. After the 
final wash, the resin was resuspended in 5ml of soluble cell lysate and incubated 
at room temperature for 1 hour in a tube rotator. The suspension was centrifuged 
at 1000 x g for 5min, a 100ml sample of the supernatant was stored for further 
analysis labelled as “Flowthrough” or “FT” and the resin was washed three times 
with HaloTag Protein Purification Buffer. The protein of interest was removed from 
the resin by adding 1ml of 6% TEV Protease (Promega, UK) and incubating at 
room temperature in tube rotator for 1 hour. Simultaneously, 10µl of 6% TEV 
Protease were added to 50µl of soluble cell lysate, incubated at room temperature 
for 1 hour and stored for analysis as “S-TEV”.
The resin was centrifuged at 3000 x g for 5 minutes, the supernatant was taken, 
the resin was resuspended in 1ml of HaloTag Protein Purification Buffer, 
centrifuged again at 3 000 x g for 5 minutes and the second supernatant was 
mixed with the first supernatant. A sample of 100µl was labelled as “elute 1” or 
“E1” and stored for analysis. 
TEV protease has a x6 His-Tag so the enzyme was removed from the first elute by 
adding 50µl of 50% HisLink Resin (Promega, UK) and incubating at room 
temperature for 20 minutes in a tube rotator. The suspension was centrifuged at 
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1000 x g for 5 minutes, supernatant was filter sterilised and a 100µl sample was 
stored as “elute 2” or “E2”.
2.9.4 Anion exchange chromatography (AEC)
The original protocol published in the HaloTag System manual indicates that the 
second elute should be the purified protein. However, an additional step  was 
included in later protein preparations after detecting HaloTag associated 
chaperonins in the first purified protein. This is explained in more detail in the 
results section.
Elute 2 was dialysed in a 10K MWCO dialysis membrane against 2L of AEC start 
buffer (20mM Tris-HCl, pH8.0) at 4ºC for 24 hours. Dialysed protein preparation 
was taken out of the dialysis membrane and transferred to a 1ml HiTrap  Capto Q 
column (GE Healthcare, UK) using a peristaltic pump. The protein was then eluted 
in an ÄKTAPrime purifier (GE Healthcare, UK) by increasing concentrations of the 
elution buffer (150mM Tris-HCl, 1M NaCl, pH8.0) and retrieving in 1ml fractions.
Fractions were analysis by  SDS-PAGE stained with Coomassie blue. The fraction 
containing the protein of interest (judged by molecular weight) was dialysed 
against PBS pH7.4 at 4ºC  for 24 hours, dialysis buffer was changed for fresh PBS 
and left at 4ºC for an additional 24 hours.
Protein was taken out of dialysis, aliquoted and the concentration was measured 
with Quant-iT Protein Assay Kit (Thermo Scientific, UK).
2.0.5 SDS-PAGE and western blot
Purified protein samples, fractions obtained from protein purification and crude cell 
lysates were analysed by  gel electrophoresis either stained with Coomassie blue 
or transferred to a PVDF membrane for western blot.
45
Gels were prepared and run according to instructions of Biorad Mini Protean kit 
(Biorad, UK). The reagents needed to prepare the gels were mixed and placed in 
a gel cassette assembly with spacers with a thickness of 1mm for polymerisation. 
The final gel contained a 10% resolving gel made by adding 5ml of resolving gel 
solution to the cassette assembly  and 2ml of stacking gel solution in addition to a 
15 wells comb.
Ingredients 10% Resolving gel (10ml) Stacking gel (10ml)
Acrylamide/Bis-acrylamide 30% 
(Sigma, UK)
3.3ml 1.33ml
1.5M Tris-HCl (Sigma, UK), pH 8.8 2.5ml --------------
0.5M Tris-HCl (Sigma, UK), pH 6.8 -------------- 2.5ml
10% SDS (Fisher Scientific, UK) 100µl 100µl
dH2O 4.05ml 6.05ml
10% APS (Sigma, UK) 100µl 100µl
TEMED (Sigma, UK) 10µl 10µl
Table 12. Volume of ingredients required for preparing a polyacrylamide gel.
Samples to be analysed were diluted in 2x sample buffer (62.5 mM Tris-HCl 
pH6.8, 40% glycerol, 0.01% bromophenol blue) and heated at 70ºC for 10min on a 
dry  block heater. Denatured samples were loaded in the gels at volumes of 10µl 
per well. Electrophoresis was performed in Tris-glycine running buffer (25mM Tris 
base, 192mM glycine, 0.1% SDS) at 200V for 50min.
Coomassie blue staining
Gels were removed from cassette assembly  and dyed in Coomassie blue stain 
(0.1% Coomassie blue R250, 10% acetic acid, 50% methanol) for 1 hour. Dye was 
removed and gels were transferred to a destain solution (10% acetic acid, 50% 
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methanol) to remove excess of Coomassie blue R250. Coomassie blue destain 
solution was changed until protein bands became visible.
Western blot
After removing gels from cassette assembly, they were washed in transfer buffer 
(25mM Tris base, 190mM glycine, 20% methanol) and placed in a transfer 
sandwich assembled by  2 pads soaked in transfer buffer, 1 filter paper, 1 protein 
gel, 1 Amersham Hybond P 0.2 PVDF membrane (GE Healthcare Life Sciences, 
UK) (previously activated in methanol and washed in transfer buffer), 1 filter paper 
and 3 pads soaked in transfer buffer. Protein blotting was performed at 40V, for 90 
min in a transfer tank containing ice cold water.
The membrane was soaked in 3% milk diluted in PBS and incubated either at 4ºC 
for overnight or at 37ºC  for 1 hour. The membrane was transferred to a solution 
containing the primary  antibody diluted in 3% milk according to optimised 
conditions and incubated at 37ºC for 2 hours. The membrane was washed three 
times in PBS + 0.1% Tween and transferred to the secondary antibody solution 
diluted in 3% milk and incubated at 37ºC for 1 hour. The membrane was washed 
three times in PBS + 0.1% Tween and developed by either ECL or 4-chloro-1-
naphtol solution.
Horseradish peroxidase (HRP) detection with 4-chloro-1-naphtol solution
A developing solution was prepared by  diluting 30mg of 4-chloro-1-naphtol (Sigma, 
UK) in 10ml of methanol, 40ml PBS and 30µl hydrogen peroxide. The membrane 
was soaked in the developing solution and placed in the dark for 15 minutes. 
Finally, the membrane was washed in dH2O and photographed. Western blots 
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performed to detect the HaloTag portion of the fusion were developed by this 
procedure.
Antibody Origin Clonality
Anti-HaloTag (Promega, UK) Mouse mAb
Anti-NanHcat Mouse pAb
Anti-mouse IgG HRP conjugated (R&D Systems, UK) Goat pAb
Table 13. Origin and clonality of antibodies used for western blot. mAb = monoclonal 
antibody, pAb = polyclonal antibody.
Detection by enhanced chemiluminescence (ECL)
Due to the low sensitivity of the antibody raised against NanHcat, a different 
developing method was employed in order to increase the signal detection. The 
developing solution was prepared by adding 1ml of each detection reagent of the 
ECL Western Blotting Analysis System (GE Healthcare, UK). The membrane was 
soaked in the developing solution and incubated at room temperature for 5min. 
The membrane was carefully shaken to remove excessive solution and placed in a 
plastic bag and in an X-ray film cassette. In a dark room, a sheet of 
autoradiography film (GE Healthcare, UK) was placed on top of the membrane 
and the cassette was closed for exposure. Time of exposure was optimised 
depending on the antibodies that were used.
2.9.6 Mass spectrometry
Orbitrap  mass spectrometry  service was provided by The Advanced Mass 
Spectrometry Facility in the School of Biosciences at the University of Birmingham. 
Samples were submitted for protein identification by excising protein bands from 
Coomassie blue stained polyacrylamide gels. The samples were trypsin digested 
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in the Mass Spectrometry facility and analysed by liquid chromatography tandem 
mass spectrometry (LC MS/MS) (http://www.birmingham.ac.uk/facilities/advanced-
mass-spectrometry/about/index.aspx).
2.9.7 Neuraminidase activity assay
A neuraminidase purified from Clostridium perfringens (Sigma, UK) was used to 
make a standard curve to calculate specific activity, defined by manufacturer as: 
“One unit will hydrolyze 1.0 micromole of 2'-(4-Methylumbelliferyl)-a-D-N-
actetylneuraminic acid (MUAN) per minute at pH 5.0 at 37°C”. The enzyme was 
reconstituted at a concentration of 0.1U/µl in 0.2% BSA and stored at -20ºC. 
Afterwards, the fluorogenic substrate MUAN (Carbosynth, UK) was reconstituted 
at a concentration of 3.5mg/ml in dH2O and stored at -20ºC.
A 96 wells plate with flat bottom was used to run every assay in which columns 1 
to 6 were used to make a standard curve while columns 7 to 12 were used for 
testing the activity of samples.
2.9.7.1 Standard curve
First, 120µl of citrate-phosphates buffer (CPB) (Citric acid 0.1M + Sodium 
phosphate 0.2M pH6.5) were added to rows B1-B3 to H1-H3 and A4-A6 to G4-G6. 
Then, 200µl of CPB were added to row A1-A3 in addition to 40µl of 0.005U/µl C. 
perfringens neuraminidase. Using a multichannel pipette, 120µl were transferred 
from row A1-A3 to row B1-B3, mixed by pipetting up and down and transferred to 
the next row to make double dilutions. Dilutions were made up to row H1-H3, then 
from this row, they were continued to row A4-A6 until row G4-G6. The last 120µl 
were discarded in order to have a volume of 120µl in each well. The layout for the 
assays is shown in table 14.
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2.9.7.2 Sample dilutions
Depending on the number of samples, 100µl of CPB were added per sample by 
triplicate as shown in the layout. Afterwards, 20µl of the sample to be tested were 
added to each well.
2.9.7.3 Substrate
Substrate MUAN was diluted to 300µM by adding 4.2µl of 3.5mg/ml MUAN in 
100µl of CPB per sample.
Using a multichannel pipette, 100µl of 300µM MUAN were added to each well and 
the plate was transferred to a Fluostar Omega microplate reader (BMG Labtech, 
UK) to read fluorescence at an excitation of 366 and an emission of 446 every 
minute for 2 hours.
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
Neu 
0.1 U
Neu 
0.1 U
Neu 
0.1 U
1:256 1:256 1:256 Ctrl + Ctrl + Ctrl + X8 X8 X8
1:2 1:2 1:2 1:512 1:512 1:512 X1 X1 X1 X9 X9 X9
1:4 1:4 1:4 1:1024 1:1024 1:1024 X2 X2 X2 X10 X10 X10
1:8 1:8 1:8 1:2048 1:2048 1:2048 X3 X3 X3 X11 X11 X11
1:16 1:16 1:16 1:4096 1:4096 1:4096 X4 X4 X4 X12 X12 X12
1:32 1:32 1:32 1:8192 1:8192 1:8192 X5 X5 X5 X13 X13 X13
1:64 1:64 1:64 1:16384 1:1638
4
1:16384 X6 X6 X6 X14 X14 X14
1:128 1:128 1:128 PBS PBS PBS X7 X7 X7 X15 X15 X15
Table 14. Sample layout of neuraminidase activity assay. Each sample was run by triplicate. 
Columns 1 to 6 contain neuraminidase of C. perfringens with a known specific activity 
serially diluted. Columns 7 to 12 contain test samples X = Any sample, Ctrl + = NanH23 
purified.
2.9.7.4 Neuraminidase specific activity
As a standard time point, the 15 minute read was considered. The fluorescence 
intensity read of every sample was blank corrected by  subtracting the average 
fluorescence of samples containing PBS and substrate.
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Blank corrected data were normalised to percentage using the formula:
%Neu = (A × 100)/B)
A = Blank corrected average fluorescence intensity of triplicates of each sample. 
B = average fluorescence intensity of 0.1U of C. perfringens neuraminidase. 
%Neu = Percentage of neuraminidase activity of each sample.
Using normalised values, a standard curve was made by plotting neuraminidase 
activity  units in the X axis and percentage activity  in the Y axis. Values were fitted 
into a non-linear regression curve. Unknown neuraminidase activity  values of test 
samples were calculated by  interpolating to the standard curve using a four 
parameter logistic equation:
Y = a + (d - a) / (1 + 10 ^ ((LogEC50 - X) * b))
a = Minimum Y value determined by the plateau formed by values obtained with a 
low concentration of neuraminidase (a = 0% in normalised data).
d = Maximum Y value determined by the fluorescence detected with 0.1U of 
neuraminidase (d = 100% in normalised data).
b = Hill’s slope, it describes the steepness of the curve.
Ec50 = Refers to the midpoint of the curve, also known as “Effective 
concentration”.
X = Unknown log(Neuraminidase activity units) of test sample.
Y = Percentage activity of test sample.
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Considering that data were distributed in a sigmoidal curve, samples with values of 
neuraminidase activity  that do not fit in the slope of the curve and fit either in the 
bottom or top plateau cannot be used to calculate neuraminidase activity units. 
Therefore, two cut-off points were established by plotting the data of 5 standard 
curves run independently and selecting the neuraminidase activity values of 5% 
and 95% neuraminidase activity since all the data within this range avoid the 
bottom and top  plateaus. Therefore, any sample with a neuraminidase activity 
value below 5% neuraminidase activity was considered as “below detection level”. 
If a sample value was calculated as higher than 95% neuraminidase activity, the 
result was considered as “above detection level” and the sample was analysed 
again at a higher dilution.
Figure 5. A standard curve was made by plotting the neuraminidase activity (%) (n = 3, ± SD) 
of C. perfringens neuraminidase obtained in vitro when tested at different known 
concentrations (Neuraminidase units) in order to determine the threshold values (dashed 
lines) for interpolation of test samples into the curve. Neuraminidase units were defined by 
the manufacturer of C. perfringens neuraminidase (Sigma, UK) as: “One unit will hydrolyze 
1.0 micromole of 2'-(4-Methylumbelliferyl)-a-D-N-actetylneuraminic acid (MUAN) per minute 
at  pH 5.0 at 37°C”. Neuraminidase activity was normalised considering 0.1 U of C. 
perfringens neuraminidase as 100%. The concentration of test samples (Neuraminidase 
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Units) was calculated by interpolating the normalised value of neuraminidase activity into a 
standard curve that was plotted for each assay run. Only samples with a neuraminidase 
activity between 5% and 95% were interpolated.
Finally, data were standardised by calculating the total protein concentration of the 
samples using Quant-iT Protein Assay Kit (Thermo Scientific, UK) and calculating 
specific neuraminidase activity (U/mg) (Figure 5).
2.9.8 Production of an anti-NanH antibody
NanH catalytic domain was purified by HaloTag system and anion exchange 
chromatography (described in detail in results chapters). After dialysis, the protein 
was filter sterilised using a 0.2µm pore syringe filter and diluted in alhydrogel at a 
ratio of 1:4 (NanH:alhydrogel) to a final concentration of 0.1µg/µl. 
Three MF1 mice (CharlesRiver, UK) were inoculated subcutaneously with 100µl of 
the protein suplemented with alhydrogel as an adjuvant. Therefore, each dose 
contained 10µg of purified NanH. The mice were boosted after 14 days and after 
28 days with the same dose. Mice were humanely sacrificed by exanguination by 
cardiac puncture under general anaesthesia and death was confirmed by neck 
dislocation as especified in schedule 1 of Home Office regulations.
Blood was centrifuged at 2000 x g for 5 minutes to obtain sera which were 
aliquoted and stored at -20ºC
2.10 M. haemolytica NanH catalytic domain
2.10.1 Site directed mutagenesis
Single amino acid substitutions were made with the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent, UK) using as template the plasmid 
53
pFN18KNanH23. Required primers were designed using the online tool made 
available by the supplier1.
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1 (http://www.genomics.agilent.com/primerDesignProgram.jsp).
Mutation Primer name Sequence
W164A
Q239Y
E277A
D138A
Y390D
S330A
R356A
D100A
NanH-W164A-F TCTATGTCGGATCAACAAGCGTATGGTGGGCGTGTTCC
NanH-W164A-
R
GGAACACGCCCACCATACGCTTGTTGATCCGACATAGA
NanH-Q239Y-F TGCAAGATGGTACGTTGGTTTTCCCAATTTATACCGCACATCA
AAAT
NanH-Q239Y-R ATTTTGATGTGCGGTATAAATTGGGAAAACCAACGTACCATCTT
GCA
NanH-E277A-F CACCGAACCAAAGTTCTTTAGCAAATATGGTGTTTGAACTCGA
NanH-E277A-R TCGAGTTCAAACACCATATTTGCTAAAGAACTTTGGTTCGGTG
NanH-D138A-F AGCACGCCGTTCAATGGCTCCAACGCTATTACATA
NanH-D138A-R TATGTAATAGCGTTGGAGCCATTGAACGGCGTGCT
NanH-Y390D-F GCCGCTGGTGCTGGTGATTCCTCTTTAGCCT
NanH-Y390D-R AGGCTAAAGAGGAATCACCAGCACCAGCGGC
NanH-S330A-F ACAACCAACTCAAGGCTCTGCTATCTATGTAACACTACC
NanH-S330A-R GGTAGTGTTACATAGATAGCAGAGCCTTGAGTTGGTTGT
NanH-R356A-F CAGATGGAAAGAATGATGGGTGGAAAGCGGGTGATATTACAC
TT
NanH-R356A-R AAGTGTAATATCACCCGCTTTCCACCCATCATTCTTTCCATCTG
NanH-D100A-F CTGGAATCGTGCGTATGCCCAAGATCGTATTGATC
NanH-D100A-R GATCAATACGATCTTGGGCATACGCACGATTCCAG
Table 15. List of primers used for site directed mutagenesis.
First, a copy of the plasmid with the expected mutation was made by PCR 
amplification using the required primer pair as shown in table 15. Reaction mixes 
and PCR conditions were set as follows:
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Component Concentration
10x Reaction buffer 5µl
DNA Template (pFN18KNanH23) 10ng
Primers 125ng each
dNTP mix 1µl
PfuUltra HF DNA polymerase 1µl
QuikSolution reagent 3µl
Water (Molecular grade) Made up to 50µl per reaction
Table 16. Concentration of components required for PCR using QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent, UK).
Step Temperature Time Cycles
Initial denature 95ºC 1 min 1
Denature 95ºC 50s
18Annealing 60ºC 50s
Extension 68ºC 6 min (1 min / kb)
Final extension 68ºC 7 min 1
Final hold 4ºC Indefinite
Table 17. Temperature conditions required for PCR using QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent, UK), pFN18KNanH23 plasmid as template and primers required for 
amplification of the plasmid with the desired mutation.
Methylated DNA used as a template was digested by adding 10U of Dpn I to the 
PCR mix after amplification and incubating at 37ºC for 1 hour. 
Amplified plasmid was cloned into E. coli strain XL10-Gold ultracompetent cells by 
chemical transformation. Cells were defrosted on ice and transferred to pre-chilled 
1.5 ml microfuge tubes in a volume of 45 µl per tube. One tube was set per PCR 
amplification along with one negative control and one positive control. Cells were 
supplemented with 2µl of β-mercaptoethanol to increase transformation efficiency 
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and incubated for 10 minutes. A sample of 5µl of mutated DNA was added to each 
tube, 5µl of molecular grade water were added to negative control tube and 1µl 
(~100ng) of parent pFN18KNanH23 was added to the positive control tube. The 
cells were incubated on ice for 30 minutes followed by a heat shock at 42ºC for 30 
seconds in a water bath and transferred immediately to an ice box for a 2 minute 
incubation. Finally, cells were supplemented with 500µl of NZY+ broth pre warmed 
at 42ºC and incubated at 37ºC with shaking for 1 hour.
After incubation, bacteria containing a mutated plasmid were transferred in 
volumes of 100µl to 1 plate of LB agar and 4 plates of LB + 50µg/ml kanamycin, 
they were distributed along the plate with a sterile bacterial cell spreader and 
incubated at 37º for overnight. The same procedure was repeated for control 
bacteria but only 1 LB agar and 1 LB agar + 50µg/ml kanamycin plates were 
prepared.
Around 10 colonies obtained from the mutated plasmid reactions were transferred 
to an LB + 50µ/ml kanamycin plate with a grid drawn on the outside to isolate and 
properly identify each colony. The plate was incubated at 37ºC for overnight and 
stored at 4ºC.
One colony per mutation reaction was grown in 10ml of LB broth + 50µg/ml 
kanamycin by duplicate at 37ºC with shaking for overnight. Cells were centrifuged 
and one of the obtained pellets was resuspended in 10ml of LB + 15% glycerol for 
storage at -80ºC  while the other pellet was disrupted for plasmid isolation using 
the GeneJet Plasmid Miniprep Kit (Thermo Fisher Scientific, UK).
The isolated plasmids were submitted to the Functional Genomics Laboratory in 
the School of Biosciences at the University of Birmingham for Sanger sequencing 
using primers pFN18K-seq-F, 7G and NanH-int-R2. The data was trimmed 
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according to peak quality and aligned against the sequence of pFN18KNanH23 to 
confirm the expected mutations.
Plasmids with confirmed sequence were transferred to competent E. coli KRX 
cells by chemical transformation. Obtained colonies were analysed by colony PCR 
using primers 7F and 7G in order to confirm transformation. A colony of each 
mutant was grown in 10ml of LB + 50µg/ml kanamycin at 37ºC for overnight, cells 
were concentrated by centrifugation and resuspended in 10ml of LB + 15% 
glycerol for storage at -80ºC.
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3 Sequence analysis
M. haemolytica has been reported to produce sialidase activity in cell lysates and 
culture supernatants but the protein responsible has not been studied. The locus 
of the neuraminidase NanH has been annotated in published genome sequences 
of M. haemolytica (Gioia et al., 2006).
The available sequences were retrieved from the NCBI database in order to 
compare the possible variation of nanH among isolates. The loci of other genes 
related to NanH were identified in order to formulate a hypothesis on the NanH 
export mechanism and its role in sialic acid metabolism.
The accession number and metadata of the sequences used in this study are 
shown in Table 18. The sequences were either retrieved as complete close 
genome sequences or as draft contigs. Accession numbers of single genes are 
mentioned as well. 
Three unpublished strains were included. Strain ATCC 33396 is a type strain that 
was genome sequenced as part of this project.
Accession No. Strain name ST Host Status Reference
CP011098
CP006619
CP005383
CP005972
CP006574
CP004753
CP004752
CP006957
CP006573
DQ680221
AASA01000000
ACZX01000000
ACZY01000000
AOGP01000000
ATSY01000000
ATSZ01000000
ATTA01000000
AUNK01000000
AUNL01000000
JANJ01000000
89010807 A1 Bovine BRD (Heaton et al., 2015)
USMARC_2286 A1 Bovine Healthy Smith, 2013 (Direct submission)
M42548 A1 Bovine BRD (Eidam et al., 2013)
D153 A1 Bovine BRD (Hauglund et al., 2013)
D174 A6 Bovine BRD (Hauglund et al., 2015b)
USDA-ARS-SAM-185 A6 Bovine BRD (Harhay et al., 2013)
USDA-ARS-SAM-183 A1 Bovine BRD (Harhay et al., 2013)
USDA-ARS-SAM-184 A2 Bovine Healthy Harhay, 2013 (Direct submission)
D171 A2 Bovine BRD (Hauglund et al., 2015a)
M7/2 A1 Bovine (Roehrig et al., 2007)
PHL213 / ATCC BAA-410 A1 Bovine BRD (Gioia et al., 2006)
“Ovine” A2 Ovine BRD (Lawrence et al., 2010)
“Bovine” A2 Bovine BRD (Lawrence et al., 2010)
H23 A6 Bovine BRD (Klima et al., 2013)
D193 A1 Bovine BRD (Hauglund et al., 2013)
MhBrain2012 A1 Bovine 
cerebellum
Hauglund, 2013 (Direct submission)
MhSwine2000 A1 Porcine Pneumonia Hauglund, 2013 (Direct submission)
D35 A2 Bovine BRD (Hauglund et al., 2015a)
D38 A6 Bovine BRD (Hauglund et al., 2015b)
PKL10 A1/A6 Deer 
spleen
BRD (Lawrence et al., 2014)
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Accession No. Strain name ST Host Status Reference
JPIZ01000000
LFXV01000000
LFXW01000000
LFXX01000000
LFXY01000000
LFXZ01000000
LFYA01000000
LFYB01000000
LFYC01000000
LFYD01000000
LFYE01000000
MEHR01000000
EF215852
Mh10517 Ovine BRD (Kidanemariam Gelaw et al., 2015)
T14 A6 Bovine BRD (Klima et al., 2016)
T2 A2 Bovine BRD (Klima et al., 2016)
L024A A1 Bovine BRD (Klima et al., 2016)
L044A A1 Bovine BRD (Klima et al., 2016)
L033A A2 Bovine BRD (Klima et al., 2016)
L038A A6 Bovine BRD (Klima et al., 2016)
535A A1 Bovine BRD (Klima et al., 2016)
587A A2 Bovine Healthy (Klima et al., 2016)
157-4-1 A1 Bovine Healthy (Klima et al., 2016)
3927A A6 Bovine Healthy (Klima et al., 2016)
NIVEDI/MH/1 Ovine Sahay, 2016 (Direct submission)
CECT924-Reglero-BHIB/A
ATCC 33396 / NCTC 9380 / 
CCUG 12392 / J.A. Watt 
1266&B
A2 Ovine Type strain (Angen et al., 1999). 
Whole genome sequenced by our 
group.
MexA1 A1 Unpublished 
DNA provided by Dr Morales
MexA2 A2 Unpublished 
DNA provided by Dr Morales
Table 18. Information about the sequences retrieved for comparison of genes of interest for 
this study.
3.1 Identification of sialic acid metabolism enzymes
The putative metabolic pathways and reactions in which M. haemolytica is 
predicted to degrade or synthesise Neu5Ac were retrieved from the metacyc 
database (Caspi et al., 2016). The genes codifying for the enzymes that were 
identified in the pathway were aligned against M. haemolytica whole genome 
sequences by BLAST. Out of 12 compared enzymes, 9 were identified in all strains 
with a sequence identity  that oscillated from 98 to 100%. Since the sequence of all 
enzymes was conserved within each of the analysed serotypes (i.e. A1, A2 and 
A6), the sequence of one representative strain for each serotype was used to 
identify the locus of each enzyme (Table 19).
The enzyme sequences that showed variability were NmaA, absent in A2 and with 
a 93% sequence identity between A1 and A6 (Figure 6); NmaB in which the 
identity between A1 and A6 was 96% however, the sequence in A2 was only 
around 60% to both A1 and A6 (Figure 7). Finally, the α-2,8-polysialyltransferase 
gene was only present in A2.
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Enzyme A1 (NC_021743) A2 (CP006957) A6 (CP004753)CDS Locus tag CDS Locus tag CDS Locus tag
CMP-N-
acetylneuraminate-β-
galactosamine-α-2,3-
sialyltransferase
UDP-N-
acetylglucosamine 2-
epimerase (NeuC-like)
N-acylneuraminate 
cytidylyltransferase
NeuNAc condensing 
enzyme
N-
acetylmannosamine-6-
phosphate 2-epimerase
N-acetylmannosamine 
kinase
N-acetylneuraminate 
lyase
UDP-N-acetyl-D-
mannosamine 
dehydrogenase (NmaB)
UDP-N-
acetylglucosamine 2-
epimerase (NmaA)
glucosamine-6-
phosphate deaminase
N-acetylglucosamine-6-
phosphate deacetylase
α-2,8-
polysialyltransferase
WP_006247883 F382_RS03950 AJE08613 B824_18180 AGI35814 D648_18090/
D648_18100
WP_006247885 F382_RS03960 AJE08615 B824_18200 AGI35816 D648_18120
WP_006247886 F382_RS03965 AJE08616 B824_18210 AGI35817 D648_18130
WP_006247887 F382_RS03970 AJE08617 B824_18220 AGI35818 D648_18140
WP_006253448 F382_RS07685 AJE06887 B824_920 AGI34077 D648_720
WP_006248965 F382_RS07690 AJE06888 B824_930 AGI34076 D648_710
WP_006248966 F382_RS07695 AJE06889 B824_940 AGI34075 D648_700
WP_006248280 F382_RS08015 AJE07152 B824_3570 AGI34007 D648_20
WP_006248279 F382_RS08020 N/A N/A AGI34006 D648_10
WP_006250130 F382_RS10250 AJE08978 B824_21830 AGI34498 D648_4930
WP_006250472 F382_RS10255 AJE08977 B824_21820 AGI34499 D648_4940
N/A N/A AJE06943 B824_1480 N/A N/A
Table 19. Loci of genes that  codify for enzymes involved in sialic acid metabolism identified 
in strains D153, USDA-ARS-SAM-184 and USDA-ARS-SAM-185 as representatives of 
serotypes A1, A2 and A6 respectively.
The nucleotide sequence of the enzymes that showed variability  was translated 
according to the annotated CDS. A multiple sequence alignment of the amino acid 
sequence was performed using the CLUSTALO tool. Sequence variability  was 
calculated using the EMBOSS needle protein alignment tool (Rice et al., 2000).
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Figure 6. Alignment of the NmaA sequence shows high conservation between serotype A1 
(strain D153) and A6 (strain USDA-ARS-SAM-185). The gene for NmaA was not  found in 
serotype A2.
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Figure 7. Alignment of the NmaB sequence shows high variability in A2 (~60%) compared to 
the identity between A1 and A6 (~93%).
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3.2 Autotransporters
Published sequencing data of M. haemolytica suggests the possibility of NanH 
being exported via TVSS (Gioia et al., 2006) in addition to other hypothetical 
proteins being exported by the same mechanism. The nucleotide sequences 
codifying for putative autotransporters in M. haemolytica were aligned against 
publicly available sequences using the tool BLAST. The representative sequences 
for two YadA-like and two pertactin-like proteins were taken from Gioia et al 
annotations (Gioia et al., 2006) while the ssa1 sequence was retrieved from CDS 
M62363 submitted by Lo et al (direct submission) and nanH from EF215852 
submitted by Fernández et al (direct submission). Accession numbers of query 
sequences are shown in table 20.
Accession no. Locus Description
MHA_2701 DS264703 (15307-21378) YadA-like 1
MHA_1367 DS264622 (19593-23744) YadA-like 2
MHA_0563 DS264612 (14484-18680) Pertactin-like 1
MHA_2800 DS264709 (6100-10611) Pertactin-like 2
EF215852 1-2376 Neuraminidase
M62363 1-3628 Serotype 1 specific antigen (Ssa 1)
Table 20. Accession number of putative autotransporters of M. haemolytica.
3.3 Autotransporter chaperones
The chaperones Skp, FkpA, SurA and DegP are known to aid the TVSS in E. coli 
however, they have not been described as functional proteins in Pasteurellaceae 
species. Homologues to these chaperones were found from the annotation of P. 
multocida strain PM70 genome sequence (AE004439) (May et al., 2001). No 
specific annotation was made for M. haemolytica so the sequences of P. multocida 
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putative chaperones were aligned to the available whole genome sequences of M. 
haemolytica. All sequences showed homology to at least one protein from M. 
haemolytica annotated in the genome sequence of strain M42548 (CP005383) 
(Table 21).
Chaperone id
P. multocida M. haemolytica
% identity
Accession no. Accession no. Locus
Skp AAK04077 WP_006248430 c1529879-1529088 33%
FkpA AAK03651 WP_006249898 939761-940354 84%
SurA AAK03292 WP_006250204 c1392081-1391137 51%
DegP AAK02818 WP_006249698 c1070963-1069569 72%
Table 21. Accession number of identified chaperones in P. multocida PM70 and homologues 
in M. haemolytica (CP005383).
The nucleotide sequence that codifies for each gene was aligned against available 
sequences of M. haemolytica finding a high degree of conservation among strains 
that oscillated only between 98 to 100% of sequence identity. Only  the strain 
PKL10 (Lawrence et al., 2014) had a lower identity, which was 80%. PKL10 
however, has been proposed as a new Mannheimia sp.
3.4 NanH sequence conservation
The sequence of nanH was retrieved from the NCBI nucleotide database with the 
accession number EF215852, directly submitted to NCBI by Fernández et al 
(Fernández Martínez, 2007). The sequence was aligned against the available 
sequences of M. haemolytica and the sequence of the strain 33396 using BLAST. 
A total of 30 additional sequences that matched EF215852 sequence were 
retrieved from the database. A multiple sequence alignment was performed using 
all thirty sequences and 27/30 shared 100% identity (Figure 8).
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The sequence AUNK01000051 showed the substitution G1535A which resulted in 
the amino acid substitution R512I (Figure 9). The sequence was obtained by the 
Roche (454) GS FLX titanium platform and was published as a draft therefore, 
additional sequencing needs to be performed to confirm the possible mutation.
LFYB01000017 is another draft genome obtained by Roche platform that shows a 
mutation in nanH (Figure 10). This sequence shows the deletion of A2281 that 
results in a frame shift that affects the translated sequence from residue 762 
disrupting the putative autotransporter domain without affecting the catalytic 
domain. However, the mutation must be confirmed by  additional sequencing as 
well.
The sequence of PHL213 published by Gioia et al shows an incomplete nanH 
gene due to being found at the beginning of contig18 (Gioia et al., 2006). The 
gene nanH was amplified by PCR from genomic DNA obtained from this strain and 
the sequence of the whole gene was obtained by Sanger sequencing. Additionally, 
nanH was amplified from the genomic DNA obtained from the two strains isolated 
in Mexico: MexA1 and MexA2. The sequence of strain ATCC  33396 was identified 
from the genome sequence obtained for this project.
A consensus of NanH sequence was obtained from the multiple sequence 
alignment made with publicly available sequences. Sequences of nanH obtained 
from PHL213, ATCC 33396, MexA1 and MexA2 were translated into protein 
sequence and aligned against NanH sequence consensus. The whole sequence 
obtained from ATCC 33396, MexA1 and MexA2 was identical. However, in 
PHL213, five aminoacid substitutions were found: Y77H, R107C, V156I, H158R, 
S162C (Numbering according to consensus sequence) (Figure 11).
It should be noted that automated annotation tools consider a different reading 
frame to EF215852 which contains the additional upstream sequence MEKM. 
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However, residues numbering of this project is based on the reading frame 
submitted by Fernandez et al (Fernández Martínez, 2007).
Figure 8. Multiple sequence alignment of publicly available sequences of M. haemolytica 
NanH shows a high sequence conservation.
Figure 9. Multiple sequence alignment of translated nanH sequences. The amino acid 
substitution R512I was found in AUNK01000017 due to the G1535A substitution. Matching 
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residues are shown as dots, the mutation is shown by the aminoacid single letter code 
shaded in red.
Figure 10. Multiple sequence alignment of translated nanH sequence. A frame shift in 
LFYB01000017 was found due to the A2281 deletion. Matching residues are shown as dots, 
mutations are shown by the aminoacid single letter code shaded in red.
Figure 11. Sequence alignment of NanH sequences determined by Sanger sequencing from 
strains PHL213, ATCC 33396, MexA1 and MexA2. Five substitutions where found in PHL213 
sequence. Matching residues are shown as dots, mutations are shown by the aminoacid 
single letter code shaded in red.
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The sequence of NanH was also compared to the sequence of other members of 
the Pasteurellaceae family of veterinary  importance which are NanH of H.parasuis 
and both neuraminidases of P. multocida: NanH and NanB. 
First, conservation of the neuraminidase genes of P. multocida and H.parasuis 
was evaluated by performing multiple sequence alignments using the tool 
CLUSTALO in CLC Main workbench between the published sequences of the 
genes without considering incomplete gene sequences. The three neuraminidases 
showed a degree of variation (Appendices I and II) so a consensus sequence for 
each was extracted considering the most common sequences.
A multiple sequence alignment was performed between M. haemolytica NanH and 
the consensus sequences of H.parasuis NanH, P. multocida NanH and NanB 
(Figure 12). All the sequences show a conserved RIP motif, three similar aspartate 
boxes and a semi-conserved β-barrel signal motif. Most of the catalytic residues 
are identical except for the fifth residue of NanB in which an aspartate substitutes 
the glutamate of the three NanHs.
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Figure 12. Multiple sequence alignment of M. haemolytica NanH (Mh_NanH), H.parasuis 
NanH (Hp_NanH), P. multocida NanH (Pm_NanH) and NanB (Pm_NanB). Catalytic residues 
are marked with an inverted triangle and conservative motifs are marked in a dashed 
square.
3.5 Conclusions
The loci of the enzymes required for sialic acid metabolism were identified and 
three of them were associated to a serotype. The loci of four putative 
autotransporter chaperones were identified by sequence homology to P. multocida 
Pm70 sequence. These data suggest that there is evidence in the genome 
sequence of M. haemolytica supporting the hypotheses of NanH role in the 
bacterium metabolism and its export mechanism. The next step  is to evaluate 
gene expression and functionality of the predicted proteins.
Sequence conservation of NanH was confirmed, increasing the possibility  of 
proposing it as a therapeutic prophylactic target.
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4 Prediction of NanH tertiary structure
Even though the sequence of various neuraminidases of different origin can be 
highly variable, the catalytic mechanism remains conserved. For instance, the 
neuraminidase of influenza A and B only have 30% of sequence identity  but their 
tertiary  structure and catalytic mechanism is identical (Shtyrya et al., 2009). 
Therefore, by sequence homology to known sialidases, we can predict the tertiary 
structure, mechanism and catalytic residues of NanH before attempting to solve 
the coordinates by crystallography.
For this part of the project, a 3D model was proposed, the putative key residues 
were hypothesised and they represent the basis for the laboratory work.
4.1 NanH architecture (BLAST)
The sequence of NanH obtained from GenBank database accession number 
ABN42196.1 submitted by  Fernandez-Martinez et al (Translation of EF215852) 
was compared to non-redundant protein sequences using the tool BLAST in order 
to predict the functional domains by sequence homology. Results showed a 
sialidase domain (cd15482) on the N-terminus, formed by residues A65 to T416 
and an autotransporter domain (pfam03797) on the C-terminus formed by 
residues N586 to T778. In addition to the BLAST search, NanH sequence was 
submitted to the server SignalP 4.1 and a signal peptide was predicted from M1 to 
A22 (Figure 13). 
The sequence shows a domain arrangement typical of the type V secretion system 
formed by a signal peptide that suggests export from the cytoplasm into the 
periplasmic space via Sec machinery, followed by an N-terminal passenger 
domain formed by the sialidase domain and a C-terminal β-barrel domain. An 
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additional molecular signature of the β-barrel domain was observed even though it 
was not aligned by BLAST to the pfam03797 consensus sequence. The motif (Y/
V/I/F/W)-X-(F/W) is present at the end of the sequence of NanH as YXW 
(Henderson et al., 1998).
The catalytic domain was classified in the conserved domain family  of non-viral 
sialidases (cd15482) (Figure 14). It contains a RIP motif in positions 75 to 77 
followed by three aspartate boxes formed by  residues S111-W118, S253-W260 
and S302-W309. The catalytic site was predicted to be formed by  amino acids 
R75, D100, E277, R293, R356, Y390 and E405. Finally, five blades that form the 
typical β-propeller structure of sialidases, were predicted to be formed by residues 
S74-F126, S136-V205, G218-I265, L275-F312 and S322-I378.
Figure 13. Diagram of NanH domains according to predictions made by sequence homology 
with BLAST, signal sequence prediction made with SignalP 4.1 and additional identification 
of YXW  motif in the sequence. Continuous line illustrates the length of the aminoacid 
sequence (black), overlaying arrows show the location of three Asp box motifs (bright red), 
overlaying rectangles show the RIP and YXW  motifs (purple and green respectively). 
Predicted signal peptide (blue arrow) and functional domains sialidase and β-barrel (brown) 
are shown above the sequence. Location of the putative catalytic aminoacids of the 
sialidase domain are marked with grey lines. Aminoacids that putatively form the propeller-
like folds are shown at the top (pale red arrows).
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Domain Accession no. Interval E-value
Non-viral sialidase Cd15482 65-416 2.26×10-53
Domain Accession no. Interval E-value
Autotransporter beta-
domain
Pfam03797 586-774 3.86×10-5
Figure 14. Alignment of NanH to consensus sequence of non-viral sialidases (Cd15482) and 
consensus sequence of the autotransporter domain family (Pfam03797). Residues marked 
in red are identical to the consensus sequence of the family, residues with a low 
conservation are marked in blue and unaligned residues are marked in grey.
4.2 Prediction of tertiary structure
The tertiary structure of NanH was predicted by sequence homology  using the 
server Phyre2 (Kelley and Sternberg, 2009, Kelley et al., 2015). A  multi-domain 
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model was constructed by  multi-template modelling of the whole NanH sequence 
as shown in figure 15.
Figure 15. A multidomain model was made with Phyre2 to illustrate the putative folding of 
NanH domains. However, folding into a single molecule is unlikely to exist because the 
signal peptide is thought to be cleaved after Sec translocation into the periplasmic space 
followed by cleavage of the β-barrel domain after translocation into the extracellular space. 
The predicted signal sequence is coloured in red (Residues 1 to 22) followed by residues 23 
to 62 coloured in grey which were modelled by ab initio. Predicted sialidase domain 
structure is coloured in cyan (residues 63 to 435) followed by a second region modelled by 
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ab initio in orange (residues 436 to 585). Finally, the C-terminus β-barrel in colour green 
(residues 586 to 791). A linear map illustrates the length in aminoacid residues of the 
predicted domains.
In order to obtain a final multi-domain model, the sialidase and the β-barrel 
domains were modelled by  sequence homology  at a confidence higher than 90%, 
which means that 74% of the tertiary  structure was predicted by homology to 
models solved by  crystallography (Table 22). The rest of the model was made by 
the method ab initio which predicts the secondary and tertiary structure by amino 
acid physical properties and by their interaction according to their arrangement. 
However, the latter method is less accurate therefore, confidence in the prediction 
of those areas of the model is lower.
Template 
(PDB 
accession)
Template description Alignment 
coverage
% Model 
confidence
% Identity
c1n1vA Trypanosoma rangeli sialidase in complex with 
DANA
62-435 100 31
d1n1ta2 Trypanosoma rangeli sialidase in complex with 
DANA at 1.6 A
61-435 100 33
d2ah2a2 Trypanosoma cruzi trans-sialidase in complex with 
2,3-difluorosialic acid (covalent intermediate)
61-435 100 30
c4bbwA The crystal structure of Sialidase VPI 5482 (BTSA) 
from Bacteroides thetaiotaomicron
61-415 100 29
c4fj6C Crystal structure of a glycoside hydrolase family 33, 
candidate sialidase (BDI_2946) from 
Parabacteroides distasonis ATCC 8503 at 1.90 A 
resolution
59-415 100 29
c3aehB Integral membrane domain of autotransporter Hbp 583-791 97.9 21
c3sljA Pre-cleavage Structure of the Autotransporter EspP 
- N1023A mutant
583-791 97.8 15
c2qomB The crystal structure of the E. coli EspP 
autotransporter Beta-domain
583-791 97.5 13
c3kvnA Crystal structure of the full-length autotransporter 
EstA from Pseudomonas aeruginosa
581-791 97.5 21
Table 22. Summary of data used by Phyre2 to predict  a 3D model of NanH. The first five rows 
show the top 5 coordinates used to model the sialidase domain of NanH, the remaining 
fours rows show the coordinates used to model the autotransporter domain.
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4.3 Homology to TrSA
As shown in Table 22, the sequences with the highest identity  that were used to 
make a model of the sialidase domain of NanH were those of the T. rangeli 
sialidase TrSA (Figure 16). The 3D model was constructed from residues G62 to 
L435 which showed 31% of sequence identity to the catalytic domain of TrSA 
(PDB: 1n1v).
Despite the low sequence identity, the six blades that form the β-propeller 
structure could be modelled from the predicted secondary  structure of NanH. The 
three aspartate boxes and six catalytic amino acids predicted by BLAST were 
aligned to those of TrSA (Figure 17).
Figure 16. The predicted 3D model of the NanH catalytic domain was superimposed to the 
catalytic domain of TrSA to illustrate the potential conserved architecture of NanH. The 
cartoon of the catalytic domain of NanH is shown in cyan, the cartoon of TrSA (PDB: 1n1v) 
is shown in yellow and a DANA molecule cartoon located in the catalytic site is shown 
coloured by element (carbon atoms are coloured in green and oxygen atoms are coloured in 
red). 
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Figure 17. Pairwise alignment of the catalytic domain of TrSA (PDB: 1N1V) and NanH 
(conserved aminoacids are shown in white font and red background, aminoacids with 
conserved properties are shown in red font and marked with a blue rectangle and residues 
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with no conservation are shown in black font). The secondary structure of NanH (depicted 
below the sequence) was predicted by sequence homology to the known secondary 
structure of TrSA (depicted above the sequence) and represents the basis for the 
construction of a 3D model of NanH. The residues that were predicted to form the propeller-
like folds of NanH were highlighted in different colours according to homology to known 
propellers of TrSA. Location of the sialidase motifs RIP and Asp boxes was highlighted in 
purple and orange rectangles with dashed edges. The putative catalytic residues of NanH 
were predicted to be identical to TrSA (inverted triangles above the sequence). Pairwise 
alignment and secondary structure prediction were performed by Phyre2. Secondary 
structure and pairwise alignment shading were drawn automatically by server ESPript 3.0 
(Robert and Gouet, 2014). Propellers, motifs and catalytic residues were manually 
illustrated.
Figure 18. Predicted interaction of NanH with DANA by superimposing the 3D model to the 
solved structure of TrSA in complex with DANA at a 1.6A resolution (1N1T). Blue dashed 
lines show residue coordination of the arginine triad to the carboxylic group and the 
possible interactions of Asp100 and Gln239 with OH-4 and Gln239 respectively. Yellow 
dashed line shows an additional interaction of Asp138 with OH-4. Pink dashed lines depict 
the amino acids involved in the acid/base reactions with C-2 that are required for cleavage 
of the O-linked glycan. Hydrophobic pocket formed by Trp157, Trp164, Met137 and Leu220 is 
shown in orange.
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4.4 Predicted catalytic mechanism
The 3D model of NanH was aligned against the coordinates of TrSA in complex 
with the inhibitor DANA (1N1T). Following the proposed mechanism published for 
TrSA (Amaya et al., 2003) and sequence homology to NanH, we predicted the 
function of the residues that might interact with the inhibitor according to the 
alignment to the model (Figure 18) and how they might interact with the substrate 
(Figure 19). 
The arginine triad formed was predicted to be formed by Arg75, Arg293 and 
Arg356 in NanH. Even though Arg293 of NanH was aligned against Val247 of 
TrSA, Arg293 was hypothesised to be part of the triad due to the predicted position 
in the catalytic site and its proximity to the carboxylate of Neu5Ac in the model.
In the TrSA model, Asp60 was designated as the proton donor necessary  for the 
release of the O-linked glycan (Buschiazzo et al., 2000). In the NanH structure 
prediction, Asp100 was homologous to Asp60 of TrSA therefore, it is possible that 
Asp100 acts as a proton donor. Additionally, Arg94 and Asp138 in NanH are in 
proximity to OH-4 therefore, it is possible that they interact with that hydroxyl 
group.
Amino Acids that stabilise the intermediate state by interacting with the 
oxocarbonium formed by C-2 were predicted to be formed by Glu277 and Tyr390. 
Therefore, Tyr390 might form a covalent bond with C-2 in the intermediate state 
and Glu277 participates in the acid/base reaction that results in the release of 
Neu5Ac.
A hydrophobic pocket that might accommodate the N-acetyl chain of the Neu5Ac 
derivatives was predicted to be formed by Met137, Trp157, Trp164 and Leu220.
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Figure 19. Diagram showing the proposed hydrolytic mechanism of NanH in which a 
terminal Neu5Ac is cleaved off of an α-2,3 linked sialylated glycan (R = any glycan). The 
reaction begins when the arginine triad formed by Arg75, Arg356 and Arg293 bind to a 
carboxylate in the substrate formed by C-1. The interaction induces a change in 
conformation followed by the hydroxylation of O-2 by Asp100. The glycan is now 
hydroxylated and released (ROH). The Neu5Ac molecule is stabilised as a carbocation by 
the interaction of Tyr390 and Glu277. Finally, a water molecule is used to hydroxylate the 
oxocarbonium (C-2) and the free Neu5Ac molecule is released. Nitrogen atoms are coloured 
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in blue, while oxygen atoms and carboxylic groups are coloured in red to illustrate positive 
and negative charges respectively. The Diagram was made with MarvinSketch (ChemAxon).
Figure 20. Prediction of the catalytic domain of NanH by sequence homology to NanB of 
S.pneumoniae. Arginine coordination is marked by a blue dashed line, proton transfer is 
marked by a pink dashed line, side interactions are marked by a yellow dashed line and the 
aminoacids that form the hydrophobic pocket are shown in orange.
An additional 3D model of NanH was made by Dr V. Bavro using the tools I-Tasser 
and MAFFT structural alignment for making a model similar to NanB of 
S.pneumoniae by aligning against coordinates 4XOG (Figure 20). The predicted 
catalytic domain in this model shared the same residues predicted by phyre2. 
However, Ser330 was positioned in proximity to the binding pocket, suggesting a 
coordination of the side chains of Glu277 and Arg356. In this model, only Arg94 is 
interacting with OH-4 and Asp138 is interacting with OH-9.
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4.5 Homology to Hbp and completion of β-barrel model
A model of the 3D structure of the autotransporter domain of NanH was built by 
homology to the Hbp autotransporter of E. coli. The secondary structure suggests 
the formation of a β-barrel from residues 585 to 791 however, the pore model is 
incomplete so it is possible that the residues that are immediately  next to the N-
terminus of the predicted autotransporter domain, are also part of the β-barrel 
(Figure 21). The YNW  sequence at the C-terminus suggests the presence of a β-
barrel signal. The EVNNLN motif, conserved among members of the SPATE family 
was not observed in NanH (Figure 22).
Figure 21. The predicted 3D model of the autotransporter domain of NanH (Green) shows 
incomplete homology to Hbp (Pink and yellow). The secondary structure of residues 488 to 
584 shows an amphipatic nature (Blue: hydrophilic residues. Red: hydrophobic residues) 
typical of β-barrel domains however, it is difficult to suggest the completion of the pore due 
to the prediction of an α-helix before the β-sheets formed from 519 to 541 that  could 
complete the model.
84
Figure 22. Sequence alignment of Hbp and NanH residues 436 to 791 shows a semi-
conserved β-barrel signal motif and a similar secondary structure. The motif EVNNLN, 
typical of the SPATE family, is missing in NanH.
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4.6 Conclusions
Using bioinformatic tools for sequence analysis and protein structure modelling, 
the putative functional domains of NanH were predicted. By following the known 
hydrolytic mechanism of neuraminidases, we hypothesised the structure of the 
catalytic site of NanH and its key amino acids. These data are the basis for the 
laboratory experiments performed for this project.
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5 Delineation of the catalytic domain of NanH
Sequence homology predictions of NanH showed the putative arrangement of the 
functional domains. Those results show a putative delimitation of the catalytic 
domain of NanH and suggest an extracellular export mechanism.
It is known that other neuraminidases have a delimited catalytic domain in addition 
to other domains of variable functions among species however, only sialidases 
produced by members of the Pasteurellaceae family have been predicted to have 
an autotransporter domain and therefore be exported via TVSS.
The objective in this section was to isolate an active catalytic domain in NanH in 
order to support that particular bioinformatic prediction and in the future study the 
functionality of the additional domains.
5.1 Identification of neuraminidase activity in M. haemolytica
Figure 23. Absolute (A) and specific (B) neuraminidase activity of M. haemolytica serotypes 
A1 (strain PHL213) and A2 (strain 33396) lysate fractions. The supernatant of M. haemolytica 
cultures was fractionated by molecular size using two filter devices. The cell pellets were 
lysed in a cell disrupter. Activity was detected in the >100kDa supernatant fraction and in 
both cell fractions for both strains. Graph A shows the absolute neuraminidase activity of 
the samples used for the experiment. Graph B shows the relative neuraminidase activity per 
milligram of sample.
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The strains ATCC33396 and PHL213 of M. haemolytica were grown in 200ml 
RPMI-1640 + 3% FBS (section 2.8). The cells were disrupted and the 
supernatants were concentrated using two centrifuge filter devices in order to 
obtain two solute fractions (section 2.8.1). A neuraminidase activity assay was 
performed to detect the presence or absence of neuraminidase in the supernatant 
fractions and in the soluble and insoluble cell fractions. Neuraminidase activity was 
detected in the supernatant only in the fraction of solutes higher than 100kDa.  In 
the cellular fraction, activity  was detected in both the soluble lysate and the 
insoluble debris (Figure 23).
5.2 Expression and purification of NanH
5.2.1 Cloning and expression of NanH23 (Signal peptide absent)
The construct pFN18KNanH23 was made by PCR amplification of nanH from 
genomic DNA of M. haemolytica strain 33396 using primers SgfI-NanH23-F and 
PmeI-NanH23-R. The obtained PCR product does not contain the signal peptide 
predicted to be formed by residues 1 to 22 in order to prevent the export of the 
protein to the periplasmic space and maximise cytoplasmic concentrations of the 
protein. The resulting plasmid was cloned into E. coli strain KRX for both plasmid 
replication and protein expression (Figure 24).
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Figure 24. Map of NanH23 in pFN18KNanH23. The backbone plasmid pFN18K contains a T7 
promoter region followed by a haloTag gene, a TEV protease recognition sequence, a 
cloning site that is delimited by the restriction sites SgfI and PmeI and a kanamycin 
resistance gene. The gene nanH23  was cloned into pfN18K with the restriction enzymes SgfI 
and PmeI and tagged with a HaloTag.
E. coli KRX containing pFN18KNanH23 was grown for protein expression in 50ml 
of expression media. Filter sterilised culture supernatant, cleared cell lysate and 
insoluble debris were analysed by SDS-PAGE as shown in figure 25. The size of 
the fusion between the HaloTag and NanH23 was predicted to be 121.716 kDa. 
However, the expected protein can only  be detected clearly  in the insoluble cell 
debris.
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Figure 25. Coomassie blue stained gel of NanH23 expression in E. coli KRX. Lanes on the 
left  side show samples from the culture containing 0.05% glucose (Promoter repressor) and 
0.05% Rhamnose (Promoter inducer) while lanes on the right show samples from a culture 
containing only 0.05% Glucose (Promoter repressor) (N/I = Not induced). Expected size of 
HaloTagged NanH23 = 122kDa (Band marked in red dashed rectangle).
Despite the low expression in the soluble lysate, a 500ml culture was grown in 
induction media for protein purification. The cell pellet was disrupted and HaloTag 
protein purification was performed. When the protein purification fractions were 
analysed by SDS-PAGE, a strong signal was again only  observed in the insoluble 
debris fraction (Figure 26). A band can be observed in the first elute but it does not 
have the expected size of cleaved NanH23 (i.e. 87kDa) and it is not observed in 
the second elute. In order to determine if there was active protein in any of the 
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fractions, a neuraminidase assay was performed. The results suggested that the 
protein was present although at very low concentrations that could not be detected 
by a Coomassie blue stained gel.
The second elute of protein purification (E2) that should contain a purified protein 
without HaloTag and free of TEV protease, was filter sterilised and concentrated 
using a 50KDa filter device in order to increase the signal detected by a 
Coomassie blue stained gel. The concentrated protein was analysed by SDS-
PAGE and three bands were detected as shown in figure 27.
Figure 26. Coomassie blue stained gel containing samples obtained from the different steps 
of NanH23 purification by HaloTag system. Lanes on the left side show samples from the 
culture containing 0.05% glucose and 0.05% Rhamnose while lanes on the right show 
samples from a culture containing only 0.05% Glucose (N/I = Not induced). Expected size of 
HaloTagged NanH23 = 122kDa. Expected size of TEV cleaved NanH23 = 87kDa.
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Figure 27. Coomassie blue stained gel containing NanH23 E2 after protein concentration.
The three bands were analysed by mass spectrometry. The results were 
compared to the protein database of both E. coli and M. haemolytica to determine 
if the protein preparation contained NanH and whether the bands were formed by 
degradation of the protein or an E. coli contaminant protein was present. 
When the sequence of peptides obtained from band 3 were compared to M. 
haemolytica, 34 peptides were identified as NanH (Accession A3F737) unique 
peptides. However, the comparison against E. coli also showed that 29 amino 
acids matched the sequence of chaperonin GroL (Accession A0A080GAD6). 
These data suggests that even though NanH was adequately expressed, 
chaperonines from the expression host were not completely removed and NanH 
concentration in protein preparation might be too low even after concentration in 
filter device.
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5.3 Cloning and expression of different nanH truncations
Following predictions of NanH tertiary structure by sequence homology to TrSA, 
we sought to identify the catalytic domain of NanH. Hence, four constructs with 
different truncations in the sequence were made as shown in Table 23.
Sequence diagram Putative tertiary 
structure
Cloning 
primers
NanH23
SgfI-
NanH23-F
PmeI-
NanH23-R
NanH23 ΔAT
SgfI-
NanH23-F
PmeI-
NanHH585-
R
NanH63 ΔAT
SgfI-
NanH63-F
PmeI-
NanHH585-
R
NanH23 cat (NanHcat)
SgfI-
NanH23-F
PmeI-
NanHL435-
R
NanH63 cat
SgfI-
NanH63-F
PmeI-
NanHL435-
R
Table 23. Diagrams depicting truncations made in NanH. Putative tertiary structures were 
added for clarity as the actual folding of each mutant protein was not predicted. Primer 
sequences are shown in table 11 of materials and methods section.
The constructs containing the mutations were made in plasmid backbone pFN18K, 
as previously described for NanH23, and cloned into E. coli KRX strain.
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The bacteria containing the plasmids were grown in 50ml cultures for protein 
expression. The cellular fraction was lysed for analysis of neuraminidase activity in 
culture supernatants (Figure 28), soluble cells lysates and insoluble cell debris. 
Expression was confirmed by SDS-PAGE (Figure 29) and Western blot with an 
anti-HaloTag antibody (Figure 30).
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Figure 28. Absolute (A) and specific (B) neuraminidase activity of NanH truncations 
expressed in E. coli. Constructs containing residues 23 to 63 produced neuraminidase 
activity in the cellular and extracellular fractions while constructs NanH63 ΔAT and 
NanH63cat did not show any activity. Control cells E. coli KRX without a plasmid, did not 
show any activity either.
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Figure 29. Coomassie blue stained gels showing expression of the different  truncations of 
NanH. Expected size: HaloTagged NanH23 = 122kDa, HaloTagged NanHcat = 81kDa, 
HaloTagged NanH63 cat = 77kDa, HaloTagged NanH23 ΔAT = 99kDa, HaloTagged NanH63 
ΔAT = 94kDa.
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Figure 30. Western blots using anti-HaloTag antibody and developed by chloronaphtol 
method, showing expression of NanH truncations. Expected size: HaloTagged NanH23 = 
122kDa, HaloTagged NanHcat = 81kDa, HaloTagged NanH63 cat = 77kDa, HaloTagged 
NanH23 ΔAT = 99kDa, HaloTagged NanH63 ΔAT = 94kDa.
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The mutants NanH63 ΔAT and NanH63cat, which did not contain residues 23 to 
62, lost activity completely. The bioinformatics predictions however, considered 
that the catalytic domain is formed by  a six propeller blades contained within 
residues S74 to L415 in addition to two α-helices formed by N62 to Y73 and T416 
to L435. Therefore, an additional structure contained within residues was not 
predicted by sequence homology and it seems to be essential for NanH to be 
active. Probably the additional sequence is required for proper protein folding.
Contrastingly, when the putative β-domain and linker regions were removed, the 
specific activity  was not lost and is even increased. However, we must consider 
that these results were obtained by calculating the specific neuraminidase activity 
per milligramme of total protein mass contained in the different fractions of lysed 
bacterial cultures. Despite that fact, we can conclude that residues N23 to L435 
are sufficient for neuraminidase activity. Therefore, the additional sequence might 
have an additional function.
5.4 Purification of the catalytic domain
Protein NanHcat was expressed in E. coli KRX containing plasmid 
pFN18KNanHcat in a 500ml culture in order to purify the catalytic domain of NanH 
from a soluble lysate by the HaloTag system procedure.
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Figure 31. Coomassie blue stained gel showing samples taken at different steps of 
purification of NanH63 ΔAT and NanHcat. HaloTagged NanHcat expected size = 81kDa, TEV 
cleaved NanHcat expected size = 46kDa. The bands containing the expressed protein are 
marked in red dashed rectangles. For this study, we only worked with purified NanHcat but 
NanH63 ΔAT was purified in parallel.
A Coomassie blue stained gel of the samples taken during the protein purification 
steps show that the soluble fraction of NanHcat in figure 31 shows a thicker band 
than the soluble fraction of NanH23 shown in figure 26. Additionally, the final 
elutes showed a more evident band despite still being contaminated with other 
bands which presumably are E. coli chaperonines.
We then aimed to reduce contamination so the protein was transferred to a 
CaptoQ column for cleaning the protein by  AEC. Figure 32 shows that two of the 
fractions obtained after elution contain an isolated band with a molecular weight of 
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~48KDa. According to the protein properties predicted from the sequence, 
NanHcat should have a molecular weight of 46.269 kDa when expressed fused to 
a HaloTag domain and cleaved with TEV protease.
Eluted fraction 9 was dialysed against PBS pH 7.4 and analysed for 
neuraminidase activity along with samples from previous purification steps (Figure 
33).
Figure 32. Coomassie blue stained gel of AEC purification fractions of NanHcat. The band 
from fraction 9 (marked in a red dashed rectangle) was excised for protein identification by 
mass spectrometry. 
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Figure 33. Absolute (A) and specific (B) neuraminidase activity of samples taken at  each 
step of the HaloTag and AEC purification of NanHcat.
The band seen in the fraction 9 sample was excised from the Coomassie blue 
stained gel and submitted to the Proteomics facility for mass spectrometry.
The sequence of the peptides analysed by mass spectrometry were aligned to 
proteins of E. coli (Table 24) and M. haemolytica (Table 25). Protein identification 
was determined by considering three or more unique peptides as a cut off point. 
Results showed only 4 matches to E. coli K12 proteins and only one unique 
peptide of each was recognised. Contrastingly, when the data were compared to 
proteins of M. haemolytica, NanH was identified as the top  hit with 26 unique 
peptides being recognised. Seven more proteins of M. haemolytica were matched 
but only 1 unique peptide in each was identified.
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Since mass spectrometry provided results that increase our confidence on the 
purity of the NanH catalytic domain, we sought to produce an antibody in mice that 
would recognise such region of the protein. 
Figure 34. Western blot using anti-NanHcat antibody at 1:1000 and developed by ECL. 
Culture supernatants and lysates of E. coli expressing different NanH truncations. Expected 
size: HaloTagged NanH23 = 122kDa, HaloTagged NanHcat = 81kDa, HaloTagged NanH63 cat 
= 77kDa, HaloTagged NanH23 ΔAT = 99kDa, HaloTagged NanH63 ΔAT = 94kDa.
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The antibody was used to analyse, by  western blot, the cell lysates previously 
obtained in order to confirm that NanH was expressed in the cultures (Figure 34). 
Even though the samples were standardised by  loading 10µg of the supernatant, 
10µg of soluble lysate and 5µg of insoluble lysate (concentration was reduced due 
to the low solubility  of the sample), cell fractions of E. coli expressing NanH23 and 
NanH23 ΔAT showed a weak signal that is only visible in the insoluble fraction. 
Considering that the neuraminidase activity assay showed a strong response 
compared to the negative control, NanH is presumably present but at very  low 
concentrations.
5.5 Conclusions
Expression of three active versions of NanH (NanH23, NanHcat and NanH23 
ΔAT) demonstrate that the catalytic domain of this sialidase is located within 
residues 23 and 435.
Expression of NanH63 ΔAT and NanH63 cat suggests that residues 23 to 62 are 
essential for neuraminidase activity. Probably they are required for adequate 
folding.
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6 Evaluation of NanH catalytic residues by amino 
acid substitution
The hydrolysis mechanism is highly conserved among sialidases. However, the 
interaction between key  residues might determine whether an inhibitor has an 
effect against specific neuraminidases.
According to the hydrolytic mechanism of known sialidases, the main components 
of a neuraminidase are an arginine triad that interacts with the hydroxilic group of 
Neu5Ac, an aspartic acid that acts as proton donor to the oxygen forming the α-
ketosidical link, a tyrosine and a glutamic acid that stabilise the intermediate state 
and a hydrophobic pocket that interacts with the N-acetyl group linked to C-5.
The objective at this stage was to evaluate the predictions made by sequence 
homology on the putative catalytic residues by amino acid substitutions.
6.1 Cloning and expression of mutants in NanH23 and NanHcat.
The site-directed mutations described in this chapter were initially  made using as 
template the plasmid pFN18KNanH23 and expressed in E. coli strain KRX under 
the same conditions as NanH23. As expected, the proteins were found in a higher 
proportion in the insoluble debris fraction than in the soluble lysate (Figure 35). 
The neuraminidase activity was apparently abolished after making most of the 
mutations in NanH23 but the effect could have been caused by low protein 
concentrations. Therefore, the catalytic domain formed by residues N23-L435 was 
cloned from each mutant into pFN18K with the aim of increasing expression 
(Figure 36) of soluble protein similarly to wild type NanHcat described in section 
5.4.
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Neuraminidase activity results of mutants made in both NanH23 and NanHcat 
were divided into five sections according to the rationale of the amino acid 
substitutions. The graphs show the result of the described mutations compared to 
the result obtained from lysate fractions of NanH23, NanHcat and E. coli strain 
KRX containing no plasmid. Results obtained from NanH23 and NanHcat are 
reiterated in the graphs for clarity.
Figure 35. Western blot showing expression of mutants made in NanH23 using a 
monoclonal anti-HaloTag antibody. Expected size of all proteins is 122kDa. 
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Figure 36. Western blot showing expression of mutants made in NanHcat using monoclonal 
anti-Halo Tag antibody at a 1:4000 concentration and developed with ECL. Strong signal 
makes visualisation difficult  therefore, these results only confirm the expression of a 
HaloTagged protein in the soluble lysate and insoluble cell debris. Only in E277A mutant, 
the molecular size can be calculated. Expected size of all proteins is 81kDa.
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6.2 Disruption of arginine triad
Figure 37. Diagram showing putative arginine triad in NanH.
The arginine triad putatively formed by Arg75, Arg293 and Arg356 was disrupted 
by substituting Arg356 (Figure 37) for an alanine in order to decrease the ionic 
charge without abolishing it completely  by only removing one of the bonds to the 
carboxylic group formed by C-1 of the sialic residue. Therefore, enzymatic activity 
was expected to decrease but not to be completely lost due to the presence of 
Arg75 and Arg293.
The mutation was sufficient to abolish activity completely only  in NanH23 lysates. 
Fractions obtained from NanHcat R356A cultures clearly had lower activity  but did 
not loose it completely as the substrate was cleaved with the soluble lysate 
sample (Figure 38).
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Figure 38. Absolute (A) and specific (B) neuraminidase activity of E. Coli culture fractions 
taken after expression of NanH23 and NanHcat with an R356A substitution to represent a 
disruption in the arginine triad.
109
6.3 Disruption on stabilisation of intermediate state
Figure 39. Diagram showing putative amino acids that stabilise intermediate state.
As mentioned in chapter 1, Tyr390 is thought to form a covalent bond that 
stabilises the intermediate state, aided by  Glu277 which might be important for 
adequate positioning (Figure 39).
The first mutant had a substitution of Glu277 for an alanine in order to test if the 
Tyr390 bond could be disrupted indirectly. The mutation of both NanH23 and 
NanHcat abolished activity (Figure 40).
The second mutant contained a mutation of Tyr390 directly, which was substituted 
by an aspartate. Therefore, by removing the hydroxyl group provided by  Tyr390 
the oxocarbonium cannot be stabilised. Additionally, the proximity  of the negatively 
charged side chain of Glu277 might repel the newly added aspartate with a 
negative charge too (Figure 39). The mutation also resulted in depletion of activity 
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of both NanH23 and NanHcat (Figure 40). However, protein expression of the 
NanHcat E277A mutant was lower than the others because samples loaded for 
western blot were standardised to 10µg of total protein per well (5µg of insoluble 
fraction) and the signal detected by the anti-HaloTag antibody was weaker than 
the other mutants (Figure 36).
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Figure 40. Absolute (A) and specific (B) neuraminidase activity of E. Coli culture fractions 
taken after expression of NanH23 and NanHcat with an E277A substitution or a Y390D 
substitution to test the disruption of the intermediate state stabilisation.
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6.4 Proton donor residue
Figure 41. Diagram showing putative proton donor.
According to homology to TrSA, Asp100 is believed to hydrogenate the oxygen 
that forms the cleaved α-ketosidical linkage therefore, is thought to be essential in 
the catalytic mechanism (Figure 41). When the residue was substituted for an 
alanine, a total loss of activity was predicted. However, activity was preserved in 
the soluble lysate of the NanHcat mutant (Figure 42). Therefore, despite playing 
an important role in catalysis, Asp100 is not essential.
113
Figure 42. Absolute (A) and specific (B) neuraminidase activity of E. Coli culture fractions 
taken after expression of NanH23 and NanHcat with a D100A substitution to test whether it 
is the essential proton donor.
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6.5 Hydrophobic pocket
Figure 43. Diagram showing putative hydrophobic pocket.
A hydrophobic pocket was predicted to be formed around the N-acetyl chain of 
Nau5Ac by residues Met137, Trp157, Trp164 and Leu220. One of the Tryptophan 
residues was substituted for an alanine in order to test if the pocket stabilisation 
was compromised (Figure 43). Activity in NanH23 was only observed in the 
soluble lysate fraction while it was preserved in NanHcat but with an apparent 
decrease (Figure 44).
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Figure 44. Absolute (A) and specific (B) neuraminidase activity of E. Coli culture fractions 
taken after expression of NanH23 and NanHcat with a W164A substitution to represent an 
alteration in the hydrophobic pocket.
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6.6 Mutation of residues possibly involved indirectly
Figure 45. Diagram showing putative interactions with OH-4.
Two residues were predicted to interact with OH-4 which are Arg94 and Asp138 
(Figure 45). By substituting only one of those residues, a decrease in activity  was 
expected as the other one could be compensating the coordination. When Asp138 
was disrupted, activity was abolished completely in both NanH constructs (Figure 
47).
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Figure 46. Diagram showing alternative docking model in which Ser330 coordinates Glu277 
and Arg356.
According to the model obtained by homology to NanB, Ser330 was predicted to 
be in proximity to the catalytic residues Glu277 and R356 (Figure 46). However, in 
the model obtained with phyre2, Ser330 appears to have little influence on the 
catalytic site structure. By making an S330A mutation, a hydroxyl group that could 
be stabilising the structure was removed. Even though no activity was detected in 
the insoluble debris of the mutant made in NanH23, the activity in the supernatant 
and soluble fraction of both NanH23 and NanHcat was still present.
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Figure 47. Absolute (A) and specific (B) neuraminidase activity of E. Coli culture fractions 
taken after expression of NanH23 and NanHcat with an D138A substitution to test the 
coordination of OH-4. Additionally, the S330A was performed to assess the docking method 
based on homology to S. pneumonia NanB.
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6.7 Comparison of enzyme activity after mutation.
Neuraminidase activity data described for cell culture fractions can only provide a 
general idea of the result after making amino acid substitutions or truncations in 
the NanH sequence. Therefore, active proteins were purified by the HaloTag 
system followed by anion exchange chromatography. Additionally, NanH23 was 
purified again but the AEC step was added after HaloTag purification. 
Figure 48. Purified proteins are shown in a Coomassie blue stained gel and western blot 
using anti-NanHcat antibody at 1:1000 and developed by ECL. Expected protein size: 
NanHcat and NanHcat mutants = 46kDa, NanH23 = 122kDa, NanH23 ΔAT = 64kDa.
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Figure 49. Absolute (A) and specific (B) neuraminidase activity of the purified proteins. Most 
the purified proteins preserved the neuraminidase activity except for R356 which was only 
weakly detected by western blot therefore, the concentration might be too low for this 
mutant to show any activity.
The band observed in the Coomassie blue stained gel and western blot of both 
constructs appears to be of the same size (Figure 48). Specific neuraminidase 
activity of NanH23 was higher than NanHcat after AEC purification (Figure 49). 
In order to identify if the putative autotransporter domain could be involved in 
cleavage of the catalytic domain, the purification of NanH23 ΔAT was attempted. 
Despite showing a specific activity  comparable to NanHcat or NanH23, no band 
was detected in the Coomassie blue stained gel or western blot so confirmation 
could not be done.
The activity of purified D100A and W164 confirm a reduction in activity observed in 
the assays run with samples from bacterial culture supernatants and lysates. The 
activity  of R356A could not be deteted even though it was detected in the soluble 
cell lysate before.
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6.8 Conclusions
The complete depletion of activity seen in mutants D138A and Y390D shows that 
these two amino acid substitutions were sufficient for disrupting the catalytic site. 
Despite not being able to detect neuraminidase activity from the E277A mutant, 
different expression of the protein hinders the possibility  of reaching the same 
conclusion.
Substitutions in D100A, W164A, R356A and S330A had an effect to different 
degrees but none of them was sufficient for abolishing neuraminidase activity 
completely.
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7 Discussion
Neuraminidase activity of respiratory pathogens has proven to be important for 
colonisation of the upper respiratory  tract since mucin is a major component of 
mucosa (Caswell, 2014). In human respiratory disease, both viral and bacterial 
agents have neuraminidase activity (Air, 2012, Kadioglu et al., 2008). A viral 
neuraminidase that could be present in the ruminant disease is produced by 
BPIV-3 (Ellis, 2010). It is therefore, possible that viral neuraminidase contributes 
for debilitating the respiratory mucosa in addition to NanH.
Neuraminidase in influenza is a major antigen and virulence factor with a highly 
variable sequence but with conserved activity (Shtyrya et al., 2009). The 
pneumococcal neuraminidase NanA also has a variable sequence (King et al., 
2005). In contrast, the sequences of NanH and the P. multocida neuraminidases 
are apparently highly conserved and can therefore, be proposed as therapeutic or 
prophylactic targets in BRD.
Even though we were unable to detect NanH by  western blot in M. haemolytica 
culture supernatant, we detected neuraminidase activity in all the cell fractions. 
Mizan et al (Mizan et al., 2000), were unable to detect any of the P. multocida 
neuraminidases extracellularly. The neuraminidase activity data described in the 
work in this thesis, in addition to data published by Straus et al on M. haemolytica 
and P. multocida (Straus and Purdy, 1995), might not provide a definitive answer 
on whether M. haemolytica NanH and the P. multocida neuraminidases purified by 
Mizan et al are secreted but the possibility  has not been disregarded. Future 
experiments should identify  the optimal growth conditions for NanH expression. 
Upregulation of nanA and nanB in the presence of a sialic acid rich media was 
demonstrated in S.pneumoniae by Trappetti et al (Trappetti et al., 2009) therefore, 
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M. haemolytica could be supplemented with Neu5Ac as well in order to attempt to 
augment NanH production.
Other neuraminidases including S.pneumoniae NanA and NanB, Vibrio cholerae 
VCNA, T.rangeli TrSA, T.cruzi TcTS and Trypanosoma congolense TconTS contain 
additional lectin-like domains that increase binding to carbohydrates (Xu et al., 
2008, Moustafa et al., 2004, Waespy  et al., 2015, Buschiazzo et al., 2000). The 
tertiary  structure of lectin-like domains is a β-barrel however, the arrangement of 
the predicted secondary structure of the C-terminus domain of NanH and the 
amphipathic nature of the amino acid sequence, suggests the presence of an 
autotransporter domain. So far, there is no confirmation of a neuraminidase being 
exported by the TVSS however, P. multocida NanH and NanB (Mizan et al., 2000) 
in addition to Pseudomonas aeruginosa NanA (Soong et al., 2006) were also 
predicted to contain an autotransporter β-barrel from their sequence.
Therefore, in the case that NanH is really exported, we hypothesise that it might 
be by TVSS as the sequence suggests. A 3D model of the β-barrel domain that 
was constructed by sequence homology to Hbp shows an incomplete barrel as 
only 10 strands were modelled compared to the 12 strands formed in the E. coli 
autotransporter (Tajima et al., 2010). The autotransporter model of NanH was built 
considering residues 583 to 791 and even though the residues immediate to the 
N-terminal of the predicted β-barrel domain did not show homology to the 
additional two strands of Hbp, the amphipathic nature of the residues 520 to 582 
could complete the pore.
By removing the putative autotransporter components which are the signal 
sequence, the linker domain and the β-barrel domain (Henderson et al., 2004), the 
catalytic domain of NanH was isolated.
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The genome sequences available for M. haemolytica strains, suggest the 
presence of the TVSS chaperones Skp, FkpA, SurA and DegP which prevent 
folding of the β-barrel before reaching BamA at the outer membrane (Leo et al., 
2012). However, whether these genes are expressed or not, is unknown.
Proteins that are secreted via TVSS, require Sec translocation through the inner 
membrane. Sec translocation of NanH was predicted from the sequence of the N-
terminus which has the typical structure of a Sec translocated protein. Signal 
peptides of Sec dependent proteins are formed by an n-region containing 
positively charged residues, an h-region containing non-polar hydrophobic 
residues and a polar c-region (Kudva et al., 2013). In NanH, the n region would be 
formed by MRK, the h-region by  INQLIISPY and the c-region by FFLSILSASA. 
Constructs NanH23, NanHcat and NanHΔAT were designed considering a 
predicted signal sequence celavage site between A22 and N23 (Petersen et al., 
2011) resulting in the expression of active proteins. Current results therefore, 
support the possibility of NanH being a passenger domain.
The neuraminidase activity data obtained from M. haemolytica cultures show 
higher sialidase hydrolytic activity in the cellular fractions of M. haemolytica than in 
the supernatant fractions. These results agree with the authors who initially 
reported neuraminidase activity  of M. haemolytica (Frank and Tabatabai, 1981, 
Straus et al., 1993a). Current autotransporter models suggest that a passenger 
domain is secreted to the extracellular space by either translocation through the β-
barrel domain or the pore formed by BamA. In both models, the pore is too narrow 
for a folded protein to be translocated and the passenger domain would have to 
remain unfolded therefore, premature folding can result in reduced secretion 
efficiency (Leyton et al., 2012, Skillman et al., 2005). Higher neuraminidase activity 
in M. haemolytica cellular fractions suggests that the passenger domain is folding 
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prematurely and not being exported efficiently, probably by a reduced expression 
of one or more chaperones associated to TVSS. Work on the Shigella flexneri 
showed that when skp is deleted, the efficiency  of the autotransporter protein IcsA 
is reduced (Wagner et al., 2009). It is also possible that premature folding is taking 
place prior to inner membrane translocation hence, a cell fractionation can be 
performed in order to compare the neuraminidase activity  levels between 
cytoplasm and periplasm.
A self-cleavage site in the linker domain could not be predicted from the sequence. 
Proteins of the SPATE family are believed to be self-cleaved by  asparagine 
cyclisation in the conserved motif EVNNLN through the interaction of an aspartate 
present in the β-barrel (Barnard et al., 2007, Dautin et al., 2007, Dautin, 2010). 
The autotransporter exported proteins BrkA and pertactin produced by Bordetella 
pertussis do not have the same motif as SPATE proteins but they are thought to 
be cleaved by the same mechanism by the cyclisation of an asparagine present in 
the sequence AESNAL (Oliver et al., 2003). The NanH sequence does not contain 
any of those motifs however, the sequence SQQNIY formed by residues 501 to 
506 contains an asparagine with adjacent residues that have similar properties to 
the ones present in EVNNLN within a short α-helix in which cleavage might occur. 
Alternatively, NanH might be cleaved from the β-barrel by a different mechanism, 
probably aided by  a protease. NanH23 was purified again during the final stage of 
this project and a band with the same size as NanHcat (~48KDa) was detected by 
western blot using anti-NanH antibody. Cleavage of the protein by the β-barrel or 
an E. coli protease could not be confirmed however, these hypotheses could be 
evaluated by altering the putative self-cleavage sites in both the passenger and 
autotransporter domains.
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The functionality of the autotransporter domain could be evaluated by the deletion 
of the signal sequence in the M. haemolytica chromosome and determine whether 
the extracellular neuraminidase activity  is eliminated. Additionally, the β-signal 
motif thought to be formed by YNW  at the C-terminus of the sequence, could be 
altered in order to study an expected interaction between NanH and the BamA 
machinery in a similar way to E. coli autotransporters (Robert et al., 2006). An 
additional piece of evidence that would support the TVSS of M. haemolytica would 
be the identification of the periplasmic chaperones identified in the genome 
sequence. The sequence of M. haemolytica suggests the production of two 
pertactin-like and two YadA-like autotransporter proteins that, if functional, would 
benefit from the chaperones activity.
In order to study the catalytic domain of NanH, two 3D models were constructed 
based on homology to TrSA and S.pneumoniae NanB. Based on the TrSA model, 
constructs NanH63 cat and NanH63 ΔAT were designed however, they were not 
active compared to the constructs designed according to the signal sequence 
cleavage site prediction (i.e. NanH23, NanHcat and NanH23 ΔAT). The role of 
residues 23 to 62 is uncertain, that region of the sequence does not seem to 
contain a catalytic amino acid and were not predicted to be part of the blades that 
form the β-propeller according to both models. These results allowed the 
delimitation of two NanHcat boundaries that resulted in the expression of a highly 
soluble protein that might be useful for crystal formation and determination of the 
tertiary structure by X-ray.
Both models of NanH showed conserved catalytic residues but in order to obtain a 
model similar to NanB, Ser330 would have to coordinate two essential amino 
acids: Arg356 and Glu277. Serine coordination is not present in the NanB model 
solved by crystallography (Gut et al., 2008). However, it was necessary  for the 
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sequence of NanH to fit the coordinates of NanB and helped to discriminate 
between docking models since the TrSa based model did not consider Ser330 to 
play a role in the catalytic site. Therefore, the preservation of activity in S330A 
supported the TrSA based model.
Based on sequence homology to TrSA, Asp100 was proposed as a crucial amino 
acid that acts as a proton donor on the released O-linked glycan (Buschiazzo et 
al., 2000). However, the substitution of Asp100 with an alanine did not eliminate 
activity  completely. The influenza neuraminidase model proposes that Asp151 
(homologous to Asp100 in NanH) and the neighbouring Arg152 bind a water 
molecule that acts as proton donor (Taylor and von Itzstein, 1994). The adjacent 
residues to Asp100 (Tyr99 and Q101) could compensate as proton donors but it is 
also possible that Arg94 binds a water molecule required for the interaction despite 
not being completely adjacent to Asp100.
It is also possible that Asp100 plays a different role and even Asp138 could be the 
residue involved in cleavage of the α-ketosidical linkage since experimental data 
suggest that the latter is more crucial. The next immediate experiment would be to 
substitute Arg94 independently and in addition to the D100A mutation.
The arginine triad of sialidases is known to be responsible for the change of 
conformation in Neu5Ac that triggers catalysis (Kim et al., 2011). Experiments in 
which the neuraminidase of the Newcastle Disease Virus (NDV) has been mutated 
in a similar way by  Iorio et al (Iorio et al., 2001) and Connaris et al (Connaris et al., 
2002) but expressed in a mammalian vector, showed that the mutation of any 
arginine from the triad resulted in complete depletion of neuraminidase activity. 
Our initial results obtained after making the R356A mutation in NanH23 showed 
that activity was lost. However, when the mutation was performed in NanHcat, 
activity  was observed in the soluble lysate. Despite high conservation in the 
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catalytic site of all neuraminidases, the difference in origin (viral and bacterial) and 
expression vector are variables that must be considered when results are 
compared. It is possible that a disruption in the central arginine of the triad does 
have a dramatic effect on the activity  of the enzyme as observed with the NDV 
neuraminidase. However, we hypothesised that by mutating Arg356 for an alanine, 
folding of the binding pocket would remain stable and the other two arginines (i.e. 
Arg75 and Arg293) would be able to bind to the carboxylic group of Neu5Ac with 
the ability to change the substrate conformation to continue hydrolysis. Probably 
that effect was only  detected because NanHcat was expressed as a small 
molecule, with a delimited catalytic domain and with higher solubility, compared to 
NanH23 that is even hard to detect in a western blot.
When the amino acids that putatively stabilise the intermediate state in the 
reaction were substituted, a complete depletion of activity was observed. By 
substituting Tyr390 for a negatively charged amino acid, we hypothesised that 
such mutation would cause a collapse of the catalytic site due to a repulsion 
between the newly introduced aspartate and Glu277. The mutation resulted in 
complete activity depletion, supporting our hypothesis. However, Vavricka et al 
(Vavricka et al., 2013) performed the same mutation in the influenza 
neuraminidase observing a 100-fold decrease of activity. The substitution of 
Glu277 also abolished neuraminidase activity, supporting the typical model of 
intermediate state stabilisation by a glutamate-tyrosine interaction. 
The relevance of the work of Vavricka et al relies on the fact that they proposed 
Tyr406 as an antiviral target that could be inhibited through a covalent interaction 
with the inhibitor. Using the inhibitor 2α,3ax-difluoro-Neu5Ac, the activity of 
neuraminidases from influenza A and B viruses was abolished, including resistant 
mutants. If that conserved tyrosine can be targeted in bacterial neuraminidases as 
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well, the viral neuraminidase inhibitor could have an added value against 
sialidases of respiratory pathogens like the pneumococcal neuraminidases as 
previously proposed for zanamivir and oseltamivir (Gut et al., 2011). A  drug 
targeting tyrosine could potentially be beneficial against BRD by inhibiting both 
viral and bacterial neuraminidases produced by  BPI-3 virus and Pasteurellaceae 
bacteria respectively.
The hydrophobic pocket in which the N-acetyl group is placed has a more variable 
sequence compared to the residues directly involved in catalysis. The 
pneumococcal neuraminidase NanA has a hydrophobic pocket formed by Phe428 
and Ile427 that are in proximity to the substrate and additional hydrophobic 
residues that include Leu551 and G552 located further away (Gut et al., 2011). In 
the TrSA model, Met96, Phe114, Trp121 and Val177 form a tighter pocket but 
perform the same function (Buschiazzo et al., 2000). We predicted NanH 
hydrophobic pocket to be formed by Met137, Trp157, Trp164 and Leu220 so by 
mutating W164 for a shorter hydrophobic amino acid, the W164A was expected to 
retain activity. We also hypothesised that a wider pocket, similar to NanA, would 
increase positioning of an inhibitor. So far we can confirm that the substrate is still 
positioned in the active site so the next step  should be evaluating if neuraminidase 
inhibitors have higher binding.
Sialic acid is required for the synthesis of capsular polysaccharide of serotypes A1 
and A2 of M. haemolytica. The synthesis of A2 capsule requires the production of 
CMP-Neu5Ac from Neu5Ac through a sialyltransferase (Solana et al., 2001), 
followed by the action of a polysialyl transferase in order to obtain α2-8 linked 
polysialic acid (Lindhout et al., 2013). In contrast, the capsule of A1 requires the 
synthesis of ManNAc and ManNAcA from UDP-GlcNAc (Lo et al., 2001).
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Neuraminidase plays the role of scavenging Neu5Ac from sialylated glycoproteins 
of the host although, the scavenging pathway is only essential for P. multocida 
since M. haemolytica can synthesise Neu5Ac de novo from UDP-GlcNAc (Vimr et 
al., 2004).
The relationship  between NanH and capsule synthesis appears to be more direct 
in serotype A2 however, ManNAc can be produced by an aldolase from Neu5Ac 
(Vimr et al., 2004). If the amount of free sialic acid used for capsule synthesis is 
greater than the amount synthesised de novo, then inhibition of NanH could 
reduce the capsule quality  and the outer membrane antigens of M. haemolytica 
would become easier to detect by the immune system.
131
8 Final conclusions
Despite the efforts to eradicate BRD caused by M. Haemolytica, the disease 
remains a problem to the ruminant industry. The understanding of respiratory 
disease in humans has highlighted the importance of viral and bacterial 
neuraminidases as a potential prophylactic and therapeutic target due to the role 
that it has in facilitating colonisation. The biological role of the neuraminidases 
produced by the primary and secondary agents of BRD has not been determined 
therefore we sought to characterise the neuraminidase produced by M. 
haemolytica NanH. By performing an analysis of the sequence, we hypothesised 
that NanH is an extracellular enzyme that is exported via the TVSS. Even though 
the secretion mechanism was not confirmed experimentally, the enzymatic domain 
of NanH was delimited by cloning truncated versions of the protein and identifying 
an active catalytic domain. Owing to the fact that the sialidase domain was 
identified at the N-terminus, the hypothetical presence of a C-terminal 
autotransporter domain is still supported. The tertiary  structure of the catalytic 
domain of NanH was predicted by  sequence homology to the neuraminidase 
produced by T. rangeli, TrSA. The 3D model was supported by substituting 
homologous residues of NanH that are essential for neuraminidase activity  of 
TrSA resulting in the reduction or abolition of activity in NanH. These data 
represent the basis for the full molecular characterisation of M. haemolytica NanH 
and the initial steps for identifying the biological role of the enzyme in BRD. The 
following steps for the completion of the molecular characterisation should be the 
confirmation of the NanH secretion system, the confirmation of all the catalytic 
residues and the identification of the 3D model coordinates by crystallography. 
Finally, the complete and adequate characterisation of NanH will permit its 
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manipulation for experiments in vivo in which the enzyme can be chemically 
inhibited or genetically eliminated. Additionally, various conditions that might alter 
gene expression can be evaluated such as sialic acid or mannose availability in 
order to confirm their role in M. haemolytica metabolism.
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